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SUMMARY 
The blood-brain barrier (BBB), a unique vascular border in the central nervous system 
(CNS), has a highly selective barrier function that prevents unwanted substances from 
entering the brain. To deliver drugs into the brain, CNS delivery systems have been widely 
explored to cross the BBB. However, the lack of experimental models that can precisely 
analyze the interactions between the BBB and delivery platforms restricts successful 
clinical translation of CNS therapeutics. Despite valuable contribution of animal models to 
drug discovery, it remains difficult to conduct mechanistic studies on the barrier function 
and interactions with drugs at molecular and cellular levels. One innovative approach to 
addressing this challenge is to develop an in vitro model that mimics the essential 
physiological structure and function of the human BBB and that allows quantitative 
analysis of drug transport across the barrier in a controlled manner. The main focus of this 
thesis is on development of a microengineered human BBB model which reconstitutes the 
key structure and function of the human BBB and enables 3D capturing of nanoparticle 
distribution at tissue and cellular levels to demonstrate the mechanisms of cellular uptakes 
and BBB penetration. This BBB model may present a complementary in vitro model to 




CHAPTER 1. INTRODUCTION 
 Background 
1.1.1 High failure rate of the central nervous system (CNS) drug development 
Neurological disorders including neurodegenerative diseases, cerebrovascular 
diseases, and brain tumors are the second leading cause of death worldwide. Moreover, the 
number of people affected by neurological disorders has been increasing worldwide, with 
approximately a 15% increase of disability-adjusted life years (DALYs) since 1990.1 
However, the success rate in clinical trials for the drugs targeting neurological diseases 
remains 8.4%, which is low compared to the success rates for other drugs.2 This challenge 
is mainly due to a unique central nervous system (CNS) barrier structure, the blood-brain 
barrier (BBB).1   
1.1.2 Blood-brain barrier (BBB) 
The BBB is a highly functionalized vascular barrier of the CNS that controls the 
transport of substances between the blood and brain.3 The selective permeability of the 
BBB remains as the major challenge in development of CNS therapeutics, and at the same 
time, many CNS diseases are associated with BBB breakdown that can lead to uncontrolled 
entry of pathogens and immune cells into the brain.4 Therefore, understanding the complex 
physiology of the BBB and transport mechanisms in both physiological and pathological 
conditions is critical to study pathophysiology of the CNS diseases as well as to develop 
CNS therapeutics. 
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The BBB consists of the specialized microvascular endothelium with surrounding 
basement membrane, pericytes, and astrocytes (Figure 1.1), and these constituent cells of 
the BBB contributes to the BBB integrity and the selective barrier function.5,6 A major 
component of the BBB is the brain endothelial cells lining the blood vessels in the brain 
that are highly specialized compared to the endothelial cells in other organs. These brain 
endothelial cells are characterized with particularly strong expression of tight junctions 
(e.g. zonula occluden-1 (ZO-1), occludin (OCLN), and claudin-5 (CLDN5)), BBB-specific 
membrane transporters (e.g. glucose transporter 1 (GLUT1) and p-glycoprotein (P-gp)) and 
receptors (e.g. low-density lipoprotein receptor related protein 1 (LRP1)).7-9 Moreover, the 
apical surface membrane of the brain endothelial cells are exposed to a continuous blood 
flow with shear stress in a range between 4~20 dyne/cm2. Pericytes embedded in the 
basement membrane wrap around the endothelium and contribute to astrocytic polarization 
and microvascular stability.10 The density of pericytes along the blood vessel is high in the 
brain with the ratio between 1:1 and 1:3 (pericytes : endothelial cells),3 while the ratio in 
skeletal muscle is known to be close to 1:10.11 Although the role of pericytes in BBB 
function has not been studied much compared to other constituent cells, recent studies have 
demonstrated their critical roles in the formation and regulation of the BBB, and the 
integration of endothelial and astrocyte functions.10,12 Astrocytes form the glia limitans of 
the BBB with their end-feet contacting the blood vessels and control the influx of water 
through aquaporin-4 (AQP4).13,14 These astrocytes construct a three-dimensional (3D) 
network with their typical star-like shapes and long branches in radial distribution along 
their cell bodies.15 The function of perivascular astrocytes at the BBB in physiological and 
pathological conditions will be further discussed in the next section. 
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Figure 1.1 Structure of the blood-brain barrier. The BBB is consisting of blood vessel 
aligned with brain endothelial cells, basement membrane, pericytes, and astrocytes that 
covers the blood vessel. Endothelial cells at the blood vessel are exposed to a continuous 
blood flow and astrocytic end-feet near the blood vessel show polarized expression of 
aquaporin-4. 
 
1.1.3 Physiology of astrocytes at the BBB 
Astrocytes are highly heterogeneous cells with different functions and 
morphologies, and these cells change their phenotype in response to CNS injuries and 
diseases.16 In the healthy brain, astrocytes show long branched processes around their cell 
bodies.15 These astrocytes cover ~99% of the perivascular surface of the brain microvessels 
with their end-feet and secrete factors that control formation, maintenance, and function of 
the BBB.16 Under CNS pathological conditions, astrocytes become reactive and contribute 
to disease progression which may lead to BBB breakdown and disease progression such as 
neurodegeneration, ischemia, and infection.15,17,18 These reactive astrocytes undergo 
changes in morphology and gene expressions. Upregulation of astrocyte intermediate 
filaments (IFs) such as glial fibrillary acidic protein (GFAP) and vimentin (VIM) have been 
used as the most common hallmark of reactive astrocytes. However, IFs were not strong 
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markers to identify reactive astrocytes as the expression level of the IFs in astrocytes varies 
with the developmental stage and the IFs are widely expressed in most astrocytes even in 
non-reactive states. Recently, reactive astrocytes-specific markers including lipocalin-2 
(LCN2) and Serpin Family A Member 3 (Serpina3n), which do not identify non-reactive 
astrocytes, have been investigated.19 
Astrocytes play an important role in water and ion homeostasis with AQP4, a 
family of water channel protein that is distributed along the cell membranes. AQP4 water 
channels are predominantly localized at astrocytic end-feet processes that contact blood 
vessels, mediating the water movements between astrocytes and the vascular region 
(Figure 1.2).20,21 Localization of AQP4 in astrocytic end-feet processes relies on AQP4 
anchoring to the dystrophin associated protein complex (DAPC) consisting of α- and β-
syntrophin, α-dystrobrevin, and dystroglycans. Previous findings using animal models that 
AQP4 is involved in brain pathophysiology including glial scar formation22 and 
neuroinflammation23 have drawn increasing interest in AQP4 distribution and function. 
Figure 1.2 Water transport through aquaporin-4 at the blood-brain barrier. 
Aquaporin-4 (AQP4), water channel protein that controls water transport, is predominantly 
localized at the end-feet of astrocytes that cover the blood vessel.  
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1.1.4 In vitro models of the human BBB 
The lack of experimental models that can precisely evaluate the interactions 
between the BBB and CNS drug delivery systems restricts successful clinical translation 
of therapeutic molecules.24,25 The complex physiology of animal models makes it difficult 
to perform mechanistic studies and direct quantitative analysis of the barrier function at 
molecular and cellular levels in real time.24 Moreover, cross-species inaccuracy has led to 
failure of more than 80% of drugs in the translation from animal models to human clinical 
trials.26,27 These challenges highlight the importance of developing an in vitro model that 
mimics the essential physiological structure and function of the human BBB and that 
reproduces the key relationships of healthy and disrupted barrier functions in a controlled 
manner.  
Traditional in vitro models use a Transwell culture system that allows for co-culture 
of multiple cells in separated space and measurement of the endothelial barrier integrity 
with transendothelial electrical resistance (TEER) or permeability assays. However, these 
models cannot accurately mimic the physiological microenvironment with their limited 
ability to incorporate three-dimensional (3D) microenvironment and dynamic shear flow. 
In recent years, microengineered physiological systems, combining the fortes of 
microfluidic technology and tissue engineering, have emerged as an alternative to 
traditional in vitro models with enhanced control over physiologically relevant parameters 
that are critical in constructing a model for the organ of interest. By allowing researchers 
to expose human cell lines to physiologically relevant chemical and mechanical cues,28,29 
these biomimetic models provide the means to better balance model simplicity and 
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physiological complexity when used as preclinical drug screening tools. However, there is 
currently no physiologically relevant in vitro human BBB model that incorporate all the 
three cell components (endothelial cells, astrocytes, and pericytes) originated from human, 
3D astrocytic network, and shear flow. Especially, to date, most in vitro BBB models have 
relied on two-dimensional (2D) culture system and focused on recapitulating the 
endothelial compartment for studying molecular transport across the brain endothelium.30-
32 Although these 2D models have proved to be useful tools for drug screening, they are 
marked by the lack of physiological relevance to the 3D microenvironment in vivo.33 For 
example, when cultured on 2D substrates, astrocytes respond to this abnormal environment 
and exhibit artificial in vitro glial reactivity with increased expression of reactive markers 
that are upregulated in pathological condition in vivo.34 Moreover, some models do not 
incorporate shear flow that mimics blood flow inside the brain capillaries, although 
previous studies have shown that shear stress affects the function of the brain endothelial 
cells with their increased expression of junctional proteins and higher barrier integrity.35-37 
Previous in vitro BBB-on-chip models are listed in (Table 1.1). (Booth and Kim, 
2012)38 and (Cho et al., 2015)39 showed in vitro BBB models with non-human species such 
as rat or mouse, limiting the models in addressing species difference between humans and 
other animals. (Herland et al., 2016)40 failed to demonstrate a physiologically relevant tri-
culture model. (Bang et al., 2017)41 and (Campisi et al., 2018)42 showed a 3D tri-culture of 
brain endothelial cells, pericytes, and astrocytes; however, it remains difficult to validate 
the barrier function using TEER and assess the vascular and perivascular spaces separately 
to quantify the molecular distributions. (Park et al., 2019)43 and (Vatine et al., 2019)44 
showed double-layered culture systems like transwell models with technical advantages to 
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allow real-time measurement of TEER and direct access to vascular and perivascular space 
for quantitative assessment of barrier function; however, these models remained restricted 
to 2D astrocyte culture. 
1.1.5 Nanomedicines for CNS therapeutics 
Recent advances in nanotechnology have enabled the engineering of nanoparticle 
(NP)-based platforms for enhanced delivery of therapeutics to the CNS (Figure 1.3).45-47 
NPs are promising CNS delivery systems with multi-functionalization of their surface to 
interact with the transporters or receptors at the BBB for crossing the BBB. Moreover, their 
drug loading capacity allows stable circulation for the sustained drug delivery to target 
sites.  






3D culture of 
astrocytes 
Shear flow 
Booth and Kim, Lab Chip, 2012 x x x o 
Cho et al., Sci.Rep., 2015 x x o x 
Hawkins et al., Brain.Res., 2015 x x o x 
Herland et al., Plos One, 2016 x o o x 
Bang et al., Sci.Rep., 2017 x x o x 
Campisi et al., Biomat., 2018  
o o o x 
Vatine et al., Cell stem cell, 2019 o o x o 
Park et al., Nat.Comm., 2019 o o x o 
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Figure 1.3 Key features of nanoparticles (NPs) for systemic delivery and translocation 
of the blood brain barrier (BBB).48 Copyright 2016, Elsevier. 
In this regard, various NPs have been developed to deliver therapeutic molecules 
across the BBB more efficiently.47 For example, polymeric NPs that have a core polymer 
matrix, in which drugs can be incorporated, deliver the drugs to the targeted region with 
high controllability.49-52 Lipid-based NPs are made with biocompatible and biodegradable 
lipids that are present in biological membranes, which result in low toxicity in the body.53-
55 Especially, high-density lipoprotein (HDL)-mimetic NPs reconstitute the natural HDLs 
that are composed of apolipoproteins and phospholipids. In addition, these HDL-mimetic 
NPs can cross the BBB without additional surface modifications as the apolipoproteins 
interact with several receptors at the BBB.56-59 
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1.1.5.1 High-density lipoprotein-mimetic nanoparticles for CNS drug delivery 
HDL is a natural nanoparticle that transports cholesterols from peripheral tissues to 
the liver, contributing to the maintenance of lipid metabolism and cholesterol homeostasis 
in the body.60 Moreover, HDL transports endogenous microRNAs, vitamins, hormones, 
and proteins through blood and interstitial fluids to various organs. To facilitate the 
delivery, HDLs have high stability with long circulation time. In addition, HDLs interact 
with several receptors expressed on the cell membranes, such as scavenger receptor type 
B1 (SR-B1), low-density lipoprotein receptor (LDLR) and LDLR-related protein 1 
(LRP1). These receptors are highly expressed on brain endothelial cells, and thus, the 
HDL-mimetic NPs could facilitate the delivery of therapeutic molecules across the BBB 
via receptor-mediated transcytosis.56,61,62 
 
 Research Objectives 
The low success rate of the CNS drug development is attributed primarily to a unique 
CNS barrier structure, the blood-brain barrier (BBB). Moreover, a large number of CNS 
therapeutics fail in clinical trials primarily due to the absence of reliable preclinical models 
of human BBB. Thus, there is a growing unmet need for a human BBB model that can be 
used to study the interactions between CNS therapeutics and the BBB. Especially, a model 
that enables quantitative analysis of drug transport mechanisms and drug distribution at 
tissue and cellular levels is yet to be developed. 
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The primary goal of this work is to develop a novel microengineered human BBB 
model for testing CNS drugs. The new microengineered human BBB platform is designed 
to incorporate a tight endothelial barrier, shear flow, pericytes that cover the endothelium, 
and physiological states of human astrocytes in 3D microenvironment. The BBB model is 
then used for quantitative analysis of nanoparticle transport across the BBB at tissue and 
cell levels. Ultimately, the model will provide a reliable tool with which drug efficacy can 
be effectively predicted for complex human CNS diseases while presenting a 
complementary in vitro model to existing in vivo models for prescreening drug candidates 
in a mechanistic manner. 
 
 
Figure 1.4 Distribution of therapeutic molecules in the brain. Drugs circulating in the 
blood can cross the BBB via specific receptors or transporters. As a result, the final drug 
locations in the brain near the BBB can be predicted as follows: (1) in the blood, (2) in 
cells (brain endothelial cells, pericytes, or astrocytes) (3) in the brain parenchyma (not in 
cells) 
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 Thesis Outline 
To achieve the primary objectives, the study is divided into the following aims: 
Aim 1: Develop a microengineered human BBB model  
• Design a microfluidic device to construct the human BBB 
• Characterize the specialization of human brain microvascular endothelial 
cells as constituent cells for the BBB 
• Characterize the physiology of astrocytes in 2D and 3D 
Aim 2: Characterize the structure and function of the BBB model  
• Demonstrate the physiologically relevant structure of the BBB 
• Validate the barrier integrity of the model 
• Analyze the polarized distribution of aquaporin-4 at the BBB 
Aim 3: Evaluate nanoparticle transport and distribution on the BBB model  
• Characterize the HDL-mimetic nanoparticles synthesized with microfluidic 
technology 
• Demonstrate the brain penetrance of the HDL-mimetic nanoparticle using a 
mouse model 
• Analyze the transport and distribution of the HDL-mimetic nanoparticles 
on a chip 
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CHAPTER 2. DEVELOPMENT OF A MICROENGINEERED 
HUMAN BLOOD-BRAIN BARRIER MODEL 
 Introduction 
The blood-brain barrier (BBB) is a highly functionalized vascular border of the 
central nervous system (CNS) that regulates the transport of substances between the blood 
and brain.3 The barrier function is attributed mainly to the unique perivascular structure 
specialized by a three-dimensional (3D) network of astrocytes that communicate with 
endothelial cells and pericytes (Figure 1.1).6 Astrocytes form the glia limitans of the BBB 
with their end-feet contacting the blood vessels and control the influx of water through 
aquaporin-4 (AQP4).13,14 Pericytes embedded in the basement membrane wrap around the 
endothelium and contribute to astrocytic polarization.10 These complex cellular 
interactions at the BBB maintain its integrity and restrict the penetration of drugs, leading 
to a low success rate in the development of therapeutics for CNS diseases.5 
It is important to understand the functionality of the perivascular structures and their 
interactions with the brain microvessels to study the selective barrier function of the BBB 
which may ultimately lead to develop more effective CNS drugs that can permeate into the 
brain. However, the lack of experimental models that can precisely evaluate the 
interactions between the BBB and delivery carriers restricts successful clinical translation 
of CNS drugs.24,25 Animal models often do not predict drug responses in humans due to 
species differences.26,63,64 Moreover, the complex physiology of animal models makes it 
difficult to perform mechanistic studies and direct quantitative analysis of CNS drugs with 
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the barrier at molecular and cellular levels in real time.24 These challenges highlight the 
importance of developing an in vitro model that mimics the essential physiological 
structure and function of the human BBB and that reproduces the key relationships of 
healthy and disrupted barrier functions in a controlled manner. 
Recent advances in organ-on-a-chip technology have provided the ability to 
recapitulate the microenvironment of the BBB.65,66 Existing in vitro human BBB-on-chip 
models have made efforts to reconstitute the tight endothelial barrier function using several 
platforms that include monoculture of brain endothelial cells39 and co-culture of endothelial 
cells with astrocytes in two-dimensional (2D)38 and 3D40,41 microenvironments. A recent 
BBB model with 3D culture of endothelial cells, pericytes, and astrocytes42 enabled 
reconstitution of direct cellular interactions, resulting in the barrier function with 
permeability lower than previous in vitro models of monoculture or co-culture. However, 
it remains difficult to incorporate the complex physiology of astrocytes into the in vitro 
BBB models and demonstrate the contribution of astrocytes to the BBB’s health and 
disruption. In a healthy brain, astrocytes show branched processes around their cell 
bodies.67 In response to CNS injuries or diseases, astrocytes become reactive, which 
contributes to BBB breakdown and disease progression such as neurodegeneration, 
ischemia, and infection.17,18 Reactive astrocytes undergo changes in morphology and gene 
expressions including lipocalin-2 (LCN2) and Serpin Family A Member 3 (Serpina3n).19 
In vitro BBB models thus would be enhanced and widely useful for CNS disease modeling 
if healthy and reactive astrocytes could be reconstituted in a controlled manner. 
Here, we design a microengineered physiological system to model the human BBB 
with specialized brain endothelial cells and 3D astrocytic network (Figure 2.1). The BBB-
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specific characteristics of the human brain microvascular endothelial cells (HBMECs) are 
analyzed with their gene expression of BBB-specific markers. To demonstrate 
physiological characteristics of astrocytes in 3D, we analyze their expressions reactive 
astrocyte markers as well as morphologies. In particular, decrease in expression of LCN2, 
a strong reactive astrocyte-specific marker which is expressed only in reactive astrocytes 
in many diseases such as neuroinflammation and stroke, provide evidence of reduced 
reactive gliosis of astrocytes.19 We then set up the co-culture protocol for reconstitution of 
the BBB in our microfluidic device. Our microfluidic chip will provide a culture platform 
to reconstitute the human BBB consisting of specialized brain endothelium and 3D network 
of astrocytes with reduced reactive gliosis. 
 Results and Discussions 
2.2.1 Design a platform for a microengineered human BBB  
  Our microengineered human BBB model is designed to reconstitute the BBB 
structure with the brain vascular endothelium and human brain vascular pericytes 
Figure 2.1 Schematic of the microengineered human blood-brain barrier chip 
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(HBVPs) in direct contact with 3D network of human astrocytes (HAs) (Figure 2.1). 
The BBB chip has two compartmentalized microfluidic channel layers that combine a 
2D endothelial monolayer with a 3D brain microenvironment, enabling highly sensitive 
quantification of molecular distribution in each space independently (Figure 2.2a,b). 
The upper layer of the device mimics the vascular space of the brain microvasculature 
where an endothelial monolayer is formed on a 7 µm thick porous membrane (8 µm 
diameter pores at a density of 1E5 pores/cm2) with 16 µL/min of continuous fluid flow 
(shear stress: 4 dyne/cm2). The lower layer accommodates pericytes underneath the 
membrane and astrocytes in a 3D Matrigel (5 mg/mL) in the center channel along with 
the two side channels (Figure 2.2c). This structure allows for the 3D astrocyte culture 
in a hydrogel that is inserted into the center channel and is stably maintained by surface 
tension. Importantly, the edges of the upper channel are aligned to cover the both-side 
arrays of micropillars (Figure 2.2d) to avoid the undesirable leakage that may occur in 
the edge of a endothelial monolayer at the channel walls, which we recently 
demonstrated with a microfluidic transcellular monitor.68 The device is designed to 
have sufficient diffusive transport of culture medium components into the hydrogel 
channel within 1 hour of media refreshment in the upper and the two side channels 
(Figure 2.2e and Figure S 2.1). Moreover, the two side channels promote independent 
lateral perfusion through the hydrogel enabling efficient removal of metabolic wastes 
or unbound antibodies and, more importantly, provide the opportunity to precisely 
sample solutions perfused from the hydrogel without disturbing the cellular 
organization.    
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Figure 2.2 Structure of the microengineered chip. a, Explosion view of the device 
consisting of upper vascular layer, porous membrane, lower perivascular layer, and glass 
slide. b, A photo of the device after completing fabrication of the device (blue: upper 
channel and red: lower channels) (scale bar = 500 µm). c, Lower layer consisting of three 
parallel channels separated by series of micropillars (red: center channel) (scale bar = 500 
µm). d, Cross section of the device after fabrication (along A-B in Fig. 1c) (scale bar = 200 
µm). e, Serum transport into the 3D Matrigel in the device after 1 min and 60 min of media 
infusion into the upper and two side channels (along A'-B' in Fig. 1c). 
   
2.2.2 Selection of co-culture medium 
Since three different types of cells (HBMEC, HBVP, and HA) are co-cultured in a 
device which share the culture environment, the co-culture medium should be selected to 
provide the optimal culture microenvironment to all three types of cells. Morphologies and 
metabolic activities of cells cultured in each cell culture medium (E, endothelial cell 
medium; A, astrocyte medium; P, pericyte medium; M, microglia medium; G, glia medium 
(A+M)) and mixture of the culture medium were assessed over 3 days of culture to screen 
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the cell conditions. Here, microglia medium was included to develop a better neurovascular 
unit system including the current BBB model, in which microglia will be co-cultured for 
future studies. Morphology of cells were not significantly different between the cells 
cultured in each culture medium and in the mixed culture medium (E+G) (Figure 2.3a). 
Moreover, all three types of cells showed high cell metabolic activities in the mixed culture 
medium (E+G) after 3 days of culture, which were quantified by a (3-(4,5-dimethylthiazol-
2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) (MTS) assay 
(Figure 2.3b). 
 
Figure 2.3 Selection of co-culture medium for BBB tri-culture model. a, Morphologies 
of HBMEC, HBVP, and HA in their respective culture medium and mixed medium (E+G). 
b, Metabolic activities of HBMEC, HBVP, and HA cultured in Endothelial cell medium 
(E), Astrocyte medium (A), Pericyte medium (P), Microglia medium (M), E+ G (E:A:M= 
1:1:1:1), and E+P+G (E:P:A:M=1:1:1:1) (*p<0.05, **p<0.01, and ****p<0.001). 
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2.2.3 Verification of endothelial specialization for the BBB function 
  The brain vascular endothelium is a highly specialized gatekeeper with complex 
transport mechanisms.5,9 The critical barrier function of the BBB endothelium is 
reportedly characterized by high expressions of BBB-specific proteins69,70, including 
junctional, transporter, and receptor proteins and by high transendothelial electrical 
resistance (TEER) (i.e., low permeability).71 In addition, applications of specific human 
cell sources have enhanced the physiological relevance of in vitro models to the unique 
properties of the BBB endothelium.42 In our present study, thus, we first demonstrated 
that our brain-specific endothelial cells, when cultured with the other BBB cells (i.e., 
astrocytes and pericytes), exhibited increases in representative gene expressions 
including proteins that regulate junctional formation, carrier-mediated transport, active 
efflux, and amyloid beta (Aβ) transport (Figure 2.4a). Especially, BBB cellular 
interactions upregulated the endothelial gene expressions of the representative 
junctional proteins such as occludin (OCLN), zonula occludens-1 (ZO-1), and vascular 
endothelial cadherin (VE-cad) (Figure 2.4b) and the representative membrane 
transporters and receptors including glucose transporter 1 (GLUT1), cholesterol efflux 
regulatory protein (CERP; ATP-binding cassette sub-family A member 1, ABCA1), 








   
 
 
Figure 2.4 Gene expressions of the immortalized human brain microvascular 
endothelial cells in monoculture and triculture models. a, Heat map of RT-qPCR results 
of HBMECs in monoculture and tri-culture systems (n=3 for each condition). b,c, Gene 
expression of HBMECs in monoculture and tri-culture systems including junctional 
proteins (b) and receptor proteins (c) (n=3 for each condition, *p<0.05). 
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2.2.4 Effects of shear stress on endothelial function 
Brain endothelial cells in brain capillary are exposed to a continuous fluidic shear 
stress in a range of 4 ~ 20 dyne/cm2.72 Blood flow in the blood vessel results in shear stress 
on the vessel wall in the direction of flow. Previous studies have demonstrated that shear 
stress plays an important role in regulating brain endothelial function, including junctional 
protein expressions35-37 and barrier integrity35,37. We verified the effects of shear stress on 
the brain endothelium constructed with HBMECs in a microfluidic channel. In our 
microfluidic device, a physiological level of shear stress was responsible for inducing 
endothelial function with efflux transporter protein expression (Figure 2.5a), and 
endothelial nitric oxide synthase (eNOS) phosphorylation (Figure 2.5b,c).   
Figure 2.5 Shear effect on the brain endothelium. a, Gene expressions of HBMECs in 
monoculture under static condition (Transwell) and physiological level of shear stress 
(chip, 4 dyne/cm2). b, Confocal images of HBMECs from different shear stress conditions 
labelled with phospho-eNOS (Ser1177) (eNOS, green; DAPI, blue) (scale bars = 20 µm). 
c, Fluorescence intensities of eNOS from confocal images normalized by the average 
intensity of the static condition (n=9 for each condition, ****p<0.001). 
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2.2.5 In vivo-like morphology of 3D-cultured astrocytes 
  Not only is the vascular endothelial barrier function important to developing and 
validating in vitro BBB models, the physiological relevance provided by perivascular 
regions is also essential to precisely recapitulate the BBB structure and function. One 
difficult yet important element in reconstituting the BBB is to preserve the 
morphological and physiological characteristics of healthy astrocytes.16 Astrocytes 
reportedly restore their in vivo-like physiological properties such as morphology and 
functional reactivity in 3D culture systems.34,67 We confirmed that HAs cultured on a 
2D Matrigel-coated surface were flat and polygonal in shape (Figure 2.6a,c). However, 
HAs cultured in 3D Matrigel exhibited more in vivo-like ramified morphology (Figure 
2.6b,d). Moreover, the majority of HAs cultured in 3D featured small cell bodies with 
radially distributed thin and long branches, whereas HAs cultured in 2D exhibited 
enlarged cell bodies with less and short processes (Figure 2.6e,f).  
2.2.6 Reduced reactive gliosis of 3D-cultured astrocytes 
  Reactive astrocytes are characterized by changes in gene expression as well as 
morphology. We performed quantitative analysis on the gene expression of reactive 
gliosis markers that are upregulated in pathological conditions to support that 3D 
cultured HAs in our BBB chip are more physiologically relevant than conventional 2D 
culture systems. In particular, LCN2 plays an important role in neuroinflammation by 
mediating proinflammatory responses in injury.73 We found that reactive gliosis 
markers, vimentin (VIM) and LCN2, were downregulated in HAs cultured in 3D 
compared to those cultured in 2D, while the level of glial fibrillary acidic protein 
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(GFAP), the representative astrocyte marker, did not significantly change (Figure 2.7a). 
In addition, we confirmed that the LCN2 expression level could be further regulated in 
a dose-dependent manner in response to an inflammatory cytokine treatment with 
interleukin-1β (IL-1β) in the 3D culture as in 2D (Figure 2.7b,c). These results 
demonstrate the physiological relevance of 3D cultured HAs and indicate the potential 
Figure 2.6 Morphologies of human astrocytes (HA) cultured on 2D Matrigel coated 
surface and in 3D Matrigel. a, HAs cultured on 2D Matrigel coated surface showed flat 
polygonal shapes. b, HAs cultured in 3D Matrigel exhibited small cell bodies with radial 
distribution of long cellular processes. c,d, Representative morphology of human astrocyte 
(HA) cultured on Matrigel-coated 2D surface (c) and in 3D Matrigel (d) (scale bars = 50 
µm). e, Cell body size of HAs cultured in 2D and 3D (n=69 for 2D and 39 for 3D, 
***p<0.005). f, Process length of HAs cultured in 2D and 3D (n=1352 for 2D and 1302 for 
3D, ****p<0.001). Scale bars = 50 µm. 
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  Recent in vitro models have demonstrated the importance of cell source to 
mimic organ-specific fuction in vitro, as well as for human disease modeling.74,75 In 
particular, highly complex BBB organization requires brain-specific cells to be sourced 
appropriately for in vitro modeling, which secures the key characteristics including the 
tight barrier function and low permeability resulting from high expressions  of BBB-
specific proteins5,9,69,70, compared to human umbilical vein endothelial cells (HUVECs) 
widely used in previous models41,76 that may not closely recapitulate the unique 
properties of the brain endothelium.77 Immortalized human brain endothelial cells are 
good candidates for standardized screenings due to their availability as well as 
Figure 2.7 Reactive gliosis marker expressions of astrocytes cultured in 2D and 3D. a, 
Gene expression of reactive gliosis markers in HAs cultured in 2D and 3D (n=4 for each 
condition, ***p<0.005 and ****p<0.001 by student t test). b,c, Gene expression of LCN2 
in HAs cultured on Matrigel-coated 2D surface (b) and within 3D Matrigel (c) with IL-1β 
treatment demonstrating the ability to model reactive astrocytes more effectively in 3D 
(n=4 for each condition, **p<0.01, ***p<0.005, and ****p<0.001). 
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indefinite proliferation while preserving their properties. Previous studies using 
hCMEC/D3 in microfluidic BBB models showed their barrier function with junctional 
protein expression, TEER31, and permeability76. In our present study, we have used 
HBMEC as it has been reported that HBMEC is the most suitable and promising 
immortalized human brain endothelial cell line among the four available cell lines 
(hCMEC/D3, HBMEC, TY10, and BB19) for in vitro modeling of human BBB in terms 
of the barrier tightness and permeability.78 Moreover, the use of HBMECs validated 
their BBB-specific function with their increased gene expressions of BBB-specific 
proteins in the presence of pericytes and astrocytes.  
  Our BBB chip is designed to incorporate 3D culture of HAs into the cellular 
organization in order to recapitulate the BBB physiology and integrity. We first 
demonstrated reduced astrogliosis in 3D cultured HA with the decreased expression of 
reactive gliosis markers as well as the in vivo-like morphology. A recent significant 
study has shown that LCN2 is a reactive astrocyte-specific marker that is commonly 
induced in pathological conditions, whereas intermediate filament proteins such as 
GFAP and VIM are normally expressed by astrocytes in both physiological and 
pathological conditions.19 We demonstrated that LCN2 expression in HAs cultured in 
3D was lower than in those cultured on 2D and more importantly that IL-1β treatment 
was more effective in 3D than in 2D, indicating the greater value for neuroinflammation 
modeling. Our results suggest that the cells restore their normal responses in 3D, while 
they are already reactive in 2D culture without external stimulation, revealing that 
studies that have used astrocyte in 2D culture may have overlooked the potential 
reactivity in their model. Taken together, our model will establish the physiologically 
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relevant human BBB with the ability to control status of astrocytes from resting to 
reactive conditions as a potential for modeling of neuroinflammation and reactive 
gliosis in CNS diseases.  
 Materials and Methods 
Fabrication of the microfluidic device. The microfluidic device was fabricated with 
polydimethylsiloxane (PDMS; Sylgard 184; Dow Corning, Midland, MI, USA) using soft 
lithography.79 To create the PDMS slab for the upper layer, PDMS pre-polymer (10:1 
elastomer base to curing agent, wt/wt) was degassed and poured onto silicon wafers 
patterned with SU-8 (Microchem, Newton, MA, USA). The thin PDMS sheet for the lower 
layer of the device was created by spin coating an SU-8 patterned silicon wafer with a 
PDMS pre-polymer to a height of 250 µm. After curing the PDMS pre-polymer for 1 h at 
80˚C, inlets and outlets of the channels were formed with 1 mm diameter biopsy punch. A 
polycarbonate membrane (8 µm pore; Sterlitech Corp, Kent, WA, USA) treated with 5% 
3-aminopropyl-trienthoxysilane (APTES) solution (Sigma-Aldrich, St. Louis, MO, USA)80 
was sandwiched and bonded between the upper and lower PDMS layers using a plasma 
cleaner (Harrick Plasma, Ithaca, NY, USA). The fabricated device was then placed in a 
polystyrene box (Ted Pella Inc., Redding, CA, USA). The device and microchannels are 
sterilized with 70% ethanol and placed in a dry oven at 80˚C for 2.5 days to restore 
hydrophobicity of the PDMS surface. 
Computational fluid dynamics. Serum transport in the microfluidic channels was 
modeled with COMSOL (COMSOL, Multiphysics 5.3a, Stockholm, Sweden). The 
convection-diffusion equation was solved using the chemical species transport module. 
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The diffusion coefficient of serum was assumed to be 5.9×10-11 m2/s in culture medium81, 
and 8.0×10-11 m2/s in Matrigel82. The initial serum concentrations of culture medium and 
Matrigel was taken as 5×10-3 mol/m3 and 0 mol/m3, respectively. Matrigel and the porous 
membrane were defined as a porous medium with porosity value of 0.8 and 0.016, 
respectively. The computational simulation was performed within a microfluidic device 
without cellular components. The three-dimensional model was used with no-slip 
boundary conditions on all the walls, and the numerical grid for performing the simulations 
consisted of approximately 850,000 finite elements. 
Cell culture. Immortalized human brain microvascular endothelial cells (HBMEC; 
Innoprot, Bizkaia, Spain) at passage 5-10 were maintained in endothelial cell medium 
(Sciencell, San Diego, CA, USA) on flasks coated with 50 μg/mL fibronectin (Sigma 
Aldrich). Human brain vascular pericytes (HBVP) and human astrocytes (HA) (Sciencell) 
were cultured on 1 mg/mL poly-l-lysine (PLL, Sigma Aldrich) coated flasks and 
maintained in astrocyte and pericyte medium, respectively (Sciencell). Both primary cells 
between passages 3 and 5 were used for all experiments. Fibronectin and PLL coating 
procedures were achieved following the manufacturer’s instruction. To optimize cell 
culture condition, cell metabolic activity in different medium condition were quantified 
using a (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-
2H-tetrazolium) (MTS) assay (n = 6), which measures the formazan product by cell 
metabolic activity. CellTiter 96 AQueous One Solution Cell Proliferation Assay (Promega, 
Madison, WI, USA) was added to HBMECs, HBVPs, and HAs cultured in Endothelial cell 
medium (E), Astrocyte medium (A), Pericyte medium (P), Microglia medium (M; 
Sciencell), E+ G (E:A:M= 1:1:1:1), and E+P+G (E:P:A:M=1:1:1:1) after 3 days of culture. 
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Here, we describe 1:1 mixture of A and E as glial cell medium (G). After 4 h of incubation, 
the optical absorbance of each sample was measured at 490 nm using Cytation 5 plate 
reader (BioTek, Winooski, VT, USA). To compare HAs in 2D and 3D, HAs were seeded 
at a density of 1 x 106 cells/mL in Matrigel coated 24 wells and in 3D Matrigel (5 mg/mL). 
After 1 day of culture, cells were stimulated with 1 ng/mL and 10 ng/mL of recombinant 
human interleukin 1-beta (IL-1β; Gibco, Grand Island, NY, USA) and incubated for 
another 20 h for analysis. 
Transwell culture. Prior to seeding HBVPs on the insert membrane (facing down), the 
bottom surface of the membrane in the insert was coated with 50 µg/mL fibronectin 
(Sigma-Aldrich) for 1 h at 37 ˚C while the insert was placed upside down. Then HBVPs 
were seeded at 1 x 107 cells/mL density on the membrane and incubated for 6 h to allow 
adhesion of cells onto the fibronectin-coated membrane. Then 1 x 107 HAs were seeded 
into the well. Transwell was placed in the incubator at 37 ˚C for 6 h, and the insert was 
coated with 50 µg/mL fibronectin for 1 h at 37 ˚C. HBMECs were then seeded in the insert 
with the density of 7 x 107 cells/mL. Cells were then co-cultured for 48 h before collecting 
mRNA.  
Real-time quantitative reverse transcription polymerase chain reaction (Real-time 
qRT-PCR). Cell-specific gene expressions were quantified by qRT-PCR analysis. Briefly, 
total RNA from HBMECs and HAs were isolated and collected using the RNeasy Mini kit 
(Qiagen GmBH, Hilden, Germany). The amount of collected RNA samples were measured 
by Cytation 5 plate reader and 800 ng (HBMEC) and 280 ng (HA) of RNA were reverse-
transcribed into cDNA with T100TM Thermal Cycler (Bio-Rad, Hercules, CA, USA) using 
High-capacity cDNA Reverse Transcription kit (Applied Biosystems, Foster City, CA, 
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USA). To analyze endothelial specific gene expressions in HBMECs (n = 3), microfluidic 
qRT-PCR was performed with Flex Six IFC (Fluidigm Corp., South San Francisco, CA, 
USA) using the Fluidigm Biomark system (Fluidigm). To analyze glial reactivity of HA in 
2D and 3D culture system (n = 4), standard qRT-PCR was performed with a StepOnePlus 
Real-Time PCR system (Applied Biosystems) using TaqMan Fast Universal PCR Master 
Mix (Applied Biosystems). The target genes were assessed using commercially available 
primers (All primers listed in Table S 2.1; Applied Biosystems). The results were 
quantified by the comparative Ct method. Ct values for samples were normalized to the 
expression of the housekeeping gene, glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH; Applied Biosystems). 
Immunocytochemistry. To visualize cell-specific marker expression, 
immunocytochemistry was performed. Briefly, samples were fixed with 2% 
paraformaldehyde (PFA; Santa Cruz Biotechnology, San Diego, CA, USA) for 15 min at 
RT. After permeabilizing in 0.1% Triton X (Sigma-Aldrich) in PBS for 15 min, the samples 
were blocked with 2% bovine serum albumin (BSA; Sigma-Aldrich) in PBS for 1 h at RT. 
Subsequently, the samples were incubated with primary antibody (anti-GFAP (1:200; 
Invitrogen, Carlsbad, CA, USA)) at 4 ˚C overnight, washed three times with 1% BSA. 
Then samples were incubated with fluorescence-conjugated secondary antibody (chicken 
anti-mouse AlexaFluor 594) (1:200; Invitrogen) for 6 h at 4 ˚C to visualize targets. Nuclei 
were counterstained with 4,6-diamino-2-phenylindole (DAPI; Invitrogen) and stored in 
PBS before imaging. Fluorescently visualized samples were examined using a confocal 
microscope (LSM 700, Carl Zeiss, Oberkochen, Germany). 
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Image analysis. Quantitative analysis of cell morphology was performed using ImageJ 
(NIH, Bethesda, MD, USA). To analyze the morphology of HAs, the boundaries of cells 








 Supplementary Information 
 
Figure S 2.1 Computational fluid dynamic simulation of nutrient supply into the 
hydrogel channel over 1 h. Computational predictions of serum transport into the 
hydrogel channel (lower center channel). 
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Table S 2.1 Primers/probes information. The target genes were assessed using 






Assay ID # 
 GAPDH Glyceraldehyde-3-phosphate dehydrogenase Hs02786624_g1 
HA RT-
qPCR 
GFAP Glial fibrillary acidic protein  Hs00909233_m1 
VIM Vimentin Hs00958111_m1 
LCN2 Lipocalin-2 Hs01008571_m1 
HBMEC 
Fluidigm 
vWF von Willebrand factor Hs01109446_m1 
SELE E-selectin Hs00174057_m1 
PECAM1 Platelet and endothelial cell adhesion molecule 1 Hs01065279_m1 
VECAD Vascular endothelial cadherin Hs00170986_m1 
OCLN Occludin Hs00170162_m1 
ZO-1 Zonula occludens-1 Hs01551861_m1 
CAT1 Cationic amino acid transporter 1 (SLC7A1) Hs00931450_m1 
LAT1 L-type amino acid transporter 1 (SLC7A5) Hs00185826_m1 
OCT1 Organic cation transporter 1(SLC22A1) Hs00427552_m1 
GLUT1 Glucose transporter 1 (SLC2A1) Hs00892681_m1 
CERP cholesterol efflux regulatory protein (ABCA1) Hs01059137_m1 
P-GP P-glycoprotein 1 (ABCB1) Hs00184500_m1 
MRP1 Multidrug resistance-associated protein 1 (ABCC1) Hs01561483_m1 
LRP1 LDL receptor related protein 1 Hs00233856_m1 
AGER Advanced glycosylation end-product receptor Hs00179504_m1 
ICAM1 Intercellular adhesion molecule 1 Hs00164932_m1 







CHAPTER 3. CHARACTERIZATION OF THE STRUCTURE 
AND FUNCTION OF THE MICROENGINEERED HUMAN 
BLOOD-BRAIN BARRIER MODEL 
 Introduction 
The blood-brain barrier (BBB) is a highly functionalized vascular structure of the 
central nervous system (CNS) that controls transport of biological substances and immune 
cells between the central nervous system and the peripheral blood.6,72 This barrier function 
of the BBB is attributed to the highly specialized perivascular structure of the BBB, which 
consists of pericytes, astrocytic end-feet, and a basement membrane.4 Pericytes that wrap 
around the endothelium also have been shown to induce polarization of astrocytic end-feet 
surrounding the brain endothelium.10 Astrocytes constructing a three-dimensional (3D) 
perivascular network form the glia limitans of the BBB with their end-feet contacting the 
blood vessels and control water influx at the BBB through  the water channel aquaporin-4 
(AQP4).13,83,84 These complex and dynamic cellular interactions at the BBB maintain the 
BBB integrity, restricting the penetration of drug and leading to a low success rate in the 
delivery of therapeutics for CNS diseases.5  
Therefore, it is critical to develop an in vitro BBB model that can include all these 
required factors for better applications in drug screening and disease modeling. In recent 
years, microengineered physiological systems, combining the fortes of microfluidic 
technology and tissue engineering, have emerged as an alternative to traditional in vitro 
models with enhanced control over physiologically relevant parameters that are critical in 
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constructing a model for the organ of interest. By allowing researchers to expose human 
cell lines to physiologically relevant chemical and mechanical cues,28,29 these biomimetic 
models provide the means to better balance model simplicity and physiological complexity 
when used as preclinical drug screening tools. Existing in vitro human BBB-on-chip 
models have largely focused on modeling the endothelial barrier system,38,41,85 which is the 
representative physiological characteristics of the BBB. However, recent studies have 
reported that not only the barrier function of the brain endothelium but also the phenotypic 
characteristics of perivascular cells like astrocytes have to be well recapitulated to develop 
an in vitro human BBB model.86,87 
Our BBB model will provide unprecedented capabilities to reproduce key structural 
and functional characteristics of the human BBB by incorporating the specialized 
endothelium, pericytes that cover the endothelium, 3D astrocytic network in 
physiologically relevant extracellular matrix (ECM) material, and shear flow. Importantly, 
our BBB chip creates a 3D astrocytic network with polarized expression of AQP4. The 
BBB chip will enable visualization of the 3D cellular network at high spatial resolution 
and quantitative analysis of permeability.  
    
 Results and Discussions 
3.2.1 Microengineered human BBB with 3D astrocytic network 
We developed a high-throughput co-culture protocol (Figure S 3.1 and Figure S 
3.2), with which we were able to establish the human BBB integrity after 2.5 days of culture, 
 34 
as the culture time was also suggested and validated in previous studies.38,85 First, HBVPs 
were seeded into the center channel of the lower layer, which is coated with fibronectin, 
while the device is placed upside down. After culturing HBVPs to allow their attachment 
to the porous membrane, primary HAs, suspended in a Matrigel solution, were seeded into 
the same channel that HBVPs are cultured. Following gelation in a microfluidic channel, 
culture medium was filled into the two side channels to avoid the gel drying out. HBMECs 
were cultured into the upper luminal layer of the device to construct an endothelial 
monolayer. Twenty-four hours after seeding, culture medium was perfused through the 
luminal channel at 16 µL/min for another 24 hours to mimic fluid flow and shear stress 
applied to the brain endothelium. 
Our BBB model reproducibly maintains the 3D network of HAs with 
physiologically relevant morphology underneath the endothelial monolayer and across the 
lower channel layer (Figure 3.1a,b). The monolayers of HBMECs and HBVPs on the 
opposite sides of the 7 µm-thick porous membrane (Figure 3.1c) while the proximity and 
perfusable structure allow for the paracrine and juxtacrine signaling between the three cells. 
More importantly, our BBB chip clearly demonstrated for the first time in in vitro BBB 
models that HAs in a 3D network extend their end-feet with higher AQP4 and α-syn 
expressions right underneath the porous membrane over the basal side of the endothelium 











Figure 3.1 Cellular network in microengineered human BBB model. a, 3D 
configuration of the BBB model showing human brain microvascular endothelial cells 
(HBMECs) (ZO-1, red) and human astrocytes (HAs) (GFAP, white) (scale bar = 100 µm). 
b, Bottom view of the device with endothelial monolayer (ZO-1, red) and astrocytic 
network (GFAP, white) (scale bar = 50 µm). c, Endothelial monolayer (ZO-1, red) 
supported by a layer of HBVPs (α-SMA, green) (scale bar = 50 µm). d, Aquaporin-4 
(AQP4, yellow) and α-syntrophin (α-syn, magenta) expressions at astrocytic end-feet 
(GFAP, white) underneath a porous membrane (indicated as the dotted line) in the lower 
channel (Blue arrows indicate co-localization of AQP4 with α-syn.) (scale bar = 50 µm). 
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3.2.2  Strict endothelial barrier with low permeability 
In our BBB chip, HBMECs cultured in the vascular channel under a physiological 
shear stress (4 dyne/cm2)72 establish an intact monolayer with tight junctions (Figure 3.2a) 
while HBVPs are cultured on the other side of the porous membrane in the perivascular 
channel (Figure 3.2b,c). Permeability to 4 kDa and 40 kDa FITC-dextran measured for the 
HBMECs in the presence of the BBB cells (HBVPs and HAs) was significantly lower than 
that of the monocultured HBMECs, which confirms the tightness of the barrier in our 
microengineered BBB system (Figure 3.3a). Moreover, our model showed size-dependent 
molecular transport across the BBB (Figure 3.3a). The TEER values and permeability were 
comparable to previous BBB studies (Figure 3.3b and Table 3.1).38,42,85 The permeability 
coefficient reached as low as the values measured in vivo.88 A physiological level of shear 
stress was responsible for enhancing barrier tightness increased TEER (Figure 3.3c). 
Figure 3.2 Brain endothelium and pericytes cultured on the opposite side of a porous 
membrane. a, Tight endothelial monolayer (ZO-1, red; DAPI, blue) formed in the upper 
channel of the device. b, Pericytes cultured underneath the porous membrane where an 
endothelial monolayer is constructed on the other side (α-SMA, green; DAPI, blue). c, Bi-




Table 3.1 Permeability coefficients of current and previous BBB models. 






40 kDa FITC 
dextran 
Booth and Kim, Lab Chip., 2012 5E-6 3.5E-6 
4kDa FITC- 
dextran 
Adriani et al., Lab Chip., 2017 1.2E-5 3E-5 
10kDa FITC- 
dextran 
Wang et al., Mol Pharm., 2016 3.6E-5 6E-7 
[14C]-mannitol 
(182 Da) 
Bang et al., Sci.Rep., 2017 1.7E-5 6E-7 
20kDa FITC- 
dextran 
Campisi et al., Biomat., 2018  2.2E-6 5E-7 
10kDa FITC-
dextran 
Maoz et al., Nat Biotech., 2018 N/A 2.7E-7 
BSA-555 
(67kDa) 
Figure 3.3 Barrier integrity of the endothelial monolayer in the BBB chip. a, TEER 
measured across the membrane between the upper and lower layers without cells (No cell), 
with an endothelial monolayer (EC), and an endothelial monolayer with pericytes and 
astrocytes (BBB) (n=6 for No cell – hydrogel only, n=12 for EC and BBB, **p<0.01 and 
****p<0.001).  b, TEER measured from BBB models under different levels of shear stress 
(n=5 for No shear, n=4 for 0.4 dyne/cm2, and n= 12 for 4 dyne/cm2, *p<0.05) c, 
Permeability coefficients calculated from the diffusion of 4 kDa and 40 kDa FITC-dextran 
through a membrane (No cell), an endothelial monolayer (EC), an endothelial monolayer 
co-cultured with pericytes and astrocytes (BBB) (n=4 for each condition, *p<0.05 and 
****p<0.001 vs. No cell, #p<0.05 and ##p<0.01 vs. EC). 
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3.2.3 3D network of astrocyte in a perivascular space 
More importantly, HAs cultured in Matrigel of the perivascular channel exhibited 
a typical star-shaped morphology with radial distribution of fine branches and their 3D 
cellular network. As previously reported, 89,90 we noted that S100β labels the cytoplasm 
Figure 3.4 3D network of astrocytes in the perivascular channel. a,b, Astrocytes with 
star-shaped morphology labeled with GFAP (GFAP, white) (a) and S100β (S100β, 
magenta) (b). c, Astrocytic end-feet stretching to the endothelium in 3D cellular network 
(GFAP, white; DAPI, blue). All scale bars = 50 µm. 
Figure 3.5 3D BBB structure constructed in a device (ZO-1, red; α-SMA, green; GFAP, 
white; DAPI, blue). The fluorescence intensity profiles indicate the distribution of ZO-1, 
α-SMA, and GFAP in the image (scale bar = 50 µm). 
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and nuclei of astrocytes, whereas GFAP labels the cytoplasm and processes (Figure 3.4a,b). 
HAs created complex 3D network with their branches stretching to the endothelium formed 
in the vascular channel (Figure 3.4c). This 3D cellular structure in our BBB chip allows 
for the highly complex yet organized BBB construction (Figure 3.5).  
 
3.2.4 Polarized distribution of aquaporin-4 in the BBB chip 
  Astrocytes in the perivascular space play a role in regulating the water 
homeostasis in the brain via the water channel protein AQP4 at their end-feet 
processes.20,21 Localization of AQP4 in astrocytic end-feet processes is therefore 
important to recapitulate the BBB in homeostatic and physiological conditions. Our 
BBB model recapitulates a complex 3D network of HAs with expression of AQP4 along 
their branches while 2D culture models show diffusively expressed AQP4 in plasma 
membrane of astrocytes (Figure S 3.3). We analyzed AQP polarization by calculating 
the ratio of AQP4 labelled along astrocytic end-feet in a vascular side versus that in a 
parenchymal side of the perivascular channel as previously reported14 (Figure 3.6a) and 
by demonstrating co-localization with α-syntrophin, the immediate anchor for AQP4 
Figure 3.6 Astrocytic end-feet underneath a porous membrane. a, Schematic showing 
the location of astrocytic end-feet with Aquaporin-4 (AQP4) and α-syntrophin (α-syn) 
colocalization. b, Co-localization of AQP4 (AQP4, yellow) and α-syntrophin (α-syn, 
magenta) at astrocytic end-feet (scale bars = 20 µm). 
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that controls AQP4 polarization to astrocytic end-feet, in the model (Figure 3.6b). The 
localization of AQP4 in HAs was polarized to the astrocytic end-feet in the vascular 
side of the channel when cultured with HBMECs and HBVPs (Figure 3.7a-c). The 
polarized distribution of AQP4 was significantly induced in the presense of HBVPs, as 
previously observed in vivo.10 This finding implies that our model can mimic the water 
transport system at the BBB, which is responsible for the homeostasis of ions and water 




Figure 3.7 Polarized distribution of aquaporin-4 in the BBB chip. a, Quantitative 
analysis of AQP4 polarization by measuring AQP4 distribution in vascular and 
parenchymal side in the perivascular channel. b, Distribution of AQP4 (AQP4, yellow) 
along the cell bodies of HAs (GFAP, white; DAPI, blue) in the channel (scale bars = 50 
µm). c, Polarized expression of AQP4 to the vascular side in the perivascular channel (n=4 
for each condition, *p<0.05). 
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 Conclusions 
  Our on-chip human BBB model successfully recapitulated the key structure and 
function of the BBB featuring the highly specialized brain endothelial monolayer and 
physiological network of astrocytes. The new hybrid design combining two vertical 
layers with three parallel channels enabled the complex BBB co-culture with high 
reproducibility, not only establishing a 2D intact brain endothelium and reconstructing 
a 3D brain microenvironment with astrocytic network but also connecting the BBB 
cells in perfusable proximity for their intercellular signaling in co-culture. Moreover, 
the present BBB model is the first of its kind to show the polarized distribution of AQP4 
in perivascular astrocytes, which is critical to mimic the BBB physiology that maintains 
water and ion homeostasis in the brain. AQP4 is also involved in brain pathophysiology 
including glial scar formation22 and neuroinflammation23. Taken together, our model 
established the physiologically relevant human BBB with the ability to control status 
of astrocytes from resting to reactive conditions as a potential for modeling of 
neuroinflammation and reactive gliosis in CNS diseases.  
 
 Materials and Methods 
Fabrication of the microfluidic device. The microfluidic device was fabricated with 
polydimethylsiloxane (PDMS; Sylgard 184; Dow Corning, Midland, MI, USA) using soft 
lithography.79 To create the PDMS slab for the upper layer, PDMS pre-polymer (10:1 
elastomer base to curing agent, wt/wt) was degassed and poured onto silicon wafers 
patterned with SU-8 (Microchem, Newton, MA, USA). The thin PDMS sheet for the lower 
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layer of the device was created by spin coating an SU-8 patterned silicon wafer with a 
PDMS pre-polymer to a height of 250 µm. After curing the PDMS pre-polymer for 1 h at 
80˚C, inlets and outlets of the channels were formed with 1 mm diameter biopsy punch. A 
polycarbonate membrane (8 µm pore; Sterlitech Corp, Kent, WA, USA) treated with 5% 
3-aminopropyl-trienthoxysilane (APTES) solution (Sigma-Aldrich, St. Louis, MO, USA)80 
was sandwiched and bonded between the upper and lower PDMS layers using a plasma 
cleaner (Harrick Plasma, Ithaca, NY, USA). The fabricated device was then placed in a 
polystyrene box (Ted Pella Inc., Redding, CA, USA). The device and microchannels are 
sterilized with 70% ethanol and placed in a dry oven at 80˚C for 2.5 days to restore 
hydrophobicity of the PDMS surface. 
Cell culture. Immortalized human brain microvascular endothelial cells (HBMEC; 
Innoprot, Bizkaia, Spain) at passage 5-10 were maintained in endothelial cell medium 
(Sciencell, San Diego, CA, USA) on flasks coated with 50 μg/mL fibronectin (Sigma 
Aldrich). Human brain vascular pericytes (HBVP) and human astrocytes (HA) (Sciencell) 
were cultured on 1 mg/mL poly-l-lysine (PLL, Sigma Aldrich) coated flasks and 
maintained in astrocyte and pericyte medium, respectively (Sciencell). Both primary cells 
between passages 3 and 5 were used for all experiments. Fibronectin and PLL coating 
procedures were achieved following the manufacturer’s instruction.  
Construction of the BBB chip system. Prior to seeding HBVPs into the center channel of 
the lower layer, the channel was coated with 50 µg/mL fibronectin (Sigma-Aldrich) for 1 
h at 37 ˚C while the device was placed upside down. Then HBVPs were seeded at 1 x 107 
cells/mL density into the center channel and incubate for 6 h to allow adhesion of cells 
onto the fibronectin-coated polycarbonate membrane. Then 1 x 107 HAs suspended in a 
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100 μL of Matrigel solution (Growth factor-reduced; Corning, Corning, NY, USA) were 
seeded into the same channel that HBVPs are cultured. The final concentration of Matrigel 
was calculated to be 5 mg/mL. After gelation of Matrigel in the channel by incubating at 
37˚C for 30 min, cell culture medium was filled into the two side channels to avoid the gel 
drying out. The device was placed in the incubator at 37 ˚C for 6 h, and the upper luminal 
channel of the device was coated with 50 µg/mL fibronectin for 1 h at 37 ˚C. HBMECs 
were then seeded into the upper channel with the density of 7 x 107 cells/mL. The final cell 
number ratio between HBMECs and HBVPs in a device was 1.5:1, and the ratio between 
HBMECs and HAs was 2:1, which was optimized for HAs to cover ~99% of the 
perivascular surface of the endothelium. After 24 h of culture to stabilize cells in the 
microfluidic device, the upper channels were connected to PhD Ultra syringe pumps 
(Harvard Apparatus, Holliston, MA, USA) and exposed to the media flow with the flow 
rate of 16 µL/min to give cells the shear stress of 4 dyne/cm2, which corresponds to the 
shear stress levels in the brain.72 
Immunocytochemistry. To visualize cell-specific marker expression, 
immunocytochemistry was performed. Briefly, samples were fixed with 2% 
paraformaldehyde (PFA; Santa Cruz Biotechnology, San Diego, CA, USA) for 15 min at 
RT. After permeabilizing in 0.1% Triton X (Sigma-Aldrich) in PBS for 15 min, the samples 
were blocked with 2% bovine serum albumin (BSA; Sigma-Aldrich) in PBS for 1 h at RT. 
Subsequently, the samples were incubated with primary antibodies at 4 ˚C overnight, 
washed three times with 1% BSA. The following antibodies were used for 
immunocytochemistry: mouse anti-GFAP (1:200; Invitrogen, Carlsbad, CA, USA), rabbit 
anti-S100β (1:200; Invitrogen), and rabbit anti-AQP4 (1:200; Invitrogen). Then samples 
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were incubated with fluorescence-conjugated secondary antibodies (chicken anti-mouse 
AlexaFluor 594) (1:200; Invitrogen) for 6 h at 4 ˚C to visualize targets. Nuclei were 
counterstained with 4,6-diamino-2-phenylindole (DAPI; Invitrogen) and stored in PBS 
before imaging. Fluorescently visualized samples were examined using a confocal 
microscope (LSM 700, Carl Zeiss, Oberkochen, Germany). 
Permeability measurement. After 60 h of culture, culture medium containing 500 µg/mL 
of 4 kDa or 40 kDa FITC-dextran (Sigma-Aldrich) was introduced into the luminal channel 
of the device at 16 µL/min with a PhD Ultra syringe pump (Harvard Apparatus). 
Simultaneously, culture medium from one side channel was sampled at 4 µL/min with a 
syringe pump for 1 h. Fluorescence intensities of 500 µg/mL of FITC-dextran solution and 
the sampled solutions are measured using a Cytation 5 plate reader (n=4 for each 
condition). The dextran concentrations in the solutions were calculated with the measured 
fluorescence intensity values using a standard calibration curve.  Permeability coefficients 










 is the concentration change in the abluminal space along time, and ∆𝐶 is the 
concentration difference across the barrier. 
TEER measurement. The TEER of the endothelial monolayer formed in the device was 
measured using Ag/AgCl electrode wires (381 μm in diameter and 3 cm in length, A-M 
Systems, Sequim, WA, USA) connected to EVOM2 volt-ohmmeter (Word Precision 
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Instruments, Sarasota, FL, USA) which generates a constant 10 µA of AC current at 12.5 
Hz while measuring resistance. To reduce background resistance and error, the electrode 
wires were placed in a tygon tubing (1/32"ID x 3/32"OD, Cole-Parmer, Vernon Hills, IL, 
USA) filled with culture medium and inserted into the channels. After 1 min of 
stabilization, 5 multiple readings were averaged for each device. To calculate TEER, the 
measured resistance was multiplied by the surface area of endothelial monolayer 
overlapping with the lower channel (0.015 cm2).   
Image analysis. Quantitative analysis of cell distribution and aquaporin-4 polarization 
were performed using ImageJ (NIH, Bethesda, MD, USA). For cell distribution analysis, 
fluorescence intensity profile of each color (red, green, and white) was analyzed using 
Matlab (Mathworks, Natick, MA, USA). Distribution of AQP4 was quantified by 
measuring the fluorescence intensity profile along the z-axis in z-stack images of the 
perivascular channel using ImageJ. The lower channel was divided into the two spaces (top 
half – vascular side, bottom half – parenchymal side) and the average of the fluorescence 
intensity from each space was calculated. The averaged intensity within the top half space 
(vascular side) was divided by the averaged normalized intensity within the bottom half 
space (parenchymal side) to calculate the AQP4 polarization index. 
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Figure S 3.1 Timeline of the experiments. The procedure for cell seeding into the device is 
as follows: 1. Culture HBVPs on a porous membrane in the abluminal region, while the 
device is flipped. 2. Inject a glial cells-embedded hydrogel in the abluminal center channel. 
3. After 12 hours, culture HBMECs on a porous membrane in the luminal side for additional 







Figure S 3.2 High-throughput experimental setup. a, High-throughput experimental 
setup using multi syringe racks. b, Experimental setup for permeability assay and molecular 
sampling.   
 
Figure S 3.3 Aquaporin-4 (AQP4) and α-syntrophin (α-syn) expression in 2D 
cultured astrocytes. Confocal images of 2D monoculture of astrocytes (GFAP, white) 
showing diffusive expression of AQP4 (AQP4, yellow) and α-syn (α-syn, magenta). Scale 
bars = 50 µm. 
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CHAPTER 4. EVALUATION OF NANOPARTICLE 
TRANSPORT AND DISTRIBUTION ON A BBB MODEL 
 Introduction 
Many potential drugs for the central nervous system (CNS) diseases fail in clinical 
trials mainly due to a unique CNS barrier structure, the blood-brain barrier (BBB).1 To 
deliver drugs across this barrier, CNS delivery systems have been widely explored to cross 
the BBB,91 including nanoparticle (NP)-mediated drug delivery with ligands specific to 
BBB endothelial surface receptors.46,47 In particular, high-density lipoprotein (HDL)-
mimetic NPs have been introduced as promising CNS delivery systems due to the innate 
endogenous character to facilitate the delivery of therapeutic molecules across the BBB via 
lipoprotein receptor-mediated transcytosis.56,61,62 However, the lack of experimental 
models that can precisely evaluate the interactions between the BBB and delivery carriers 
restricts successful clinical translation of therapeutic and diagnostic NPs.24,25 Animal 
models often do not predict drug responses in humans due to species differences.26,63,64 
Moreover, the complex physiology of animal models makes it difficult to perform 
mechanistic studies and direct quantitative analysis of NPs with the barrier at molecular 
and cellular levels in real time.24 These challenges highlight the importance of developing 
an in vitro model that mimics the essential physiological structure and function of the 
human BBB and that reproduces the key relationships of healthy and disrupted barrier 
functions in a controlled manner. Moreover, effective experimental strategies that can 
quantitatively analyze the NP transport, distribution, and delivery to targeted cells or 
regions will enable robust preclinical screening of the NPs.  
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In this study, we use our microengineered human BBB model to assess NP transport 
and distribution at the BBB. The model combined with high-precision sampling and flow 
cytometric analysis enables on-chip quantification of nanoparticle transport and 
distribution in the vascular and perivascular regions at cellular and tissue levels. Our BBB 
chip may provide a reliable tool for better understanding of drug distribution and efficacy 
at the BBB in both physiological and pathological conditions. 
 
 Results and Discussions 
4.2.1 Microfluidic synthesis of the biomimetic nanoparticle   
  We synthesized a bioinspired nanoparticle that mimics the natural high-density 
lipoproteins (HDL) in our body, which have high stability and long circulation time. 
Moreover, these HDL particles are known to be able to translocate the BBB via 
lipoprotein receptors expressed at the brain endothelium such as scavenger receptor 
type B1 (SR-B1) (Figure 4.1a).46,56,92 Thus, the HDL-mimetic particles that can 
reconstitute the innate ability of the plasma HDL is a promising drug carrier for CNS 
drug delivery. 
  We used our microfluidic technology to engineer HDL-mimetic nanoparticles 
with apolipoprotein A1 (eHNP-A1) (Figure 4.1b). The microfluidic synthesis increased 
the efficiency of mixing the precursor solutions while decreased the number of 
formulation steps, resulting in high yield and homogeneity of the eHNP-A1. The eHNP-
A1 showed discoidal structure and the physiologically relevant size with a diameter of 
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10-20 nm (Figure 4.1c-e). Moreover, the microfluidic synthesis resulted in high 
reproducibility and unform sizes and composition of the eHNP-A1(Figure 4.1f).  
 
4.2.2 Brain accumulation of the biomimetic nanoparticle 
  We confirmed through a biodistribution study following intravenous injection 
of the fluorescent-dye labeled eHNP-A1s that eHNP-A1 can enter the BBB with 
approximately 3% of relative accumulation in the brain (Figure 4.2a,b and Figure S 
Figure 4.1 The engineered high-density lipoprotein mimicking nanoparticle with 
apolipoprotein-A1 (eHNP-A1). a, Schematic description of scavenger receptor type B1 
(SR-B1) mediated eHNP-A1 transcytosis. b, Schematic description of eHNP-A1 synthesis 
using the microvortex propagation mixer (µVPM). c, Discoidal eHNP-A1 consisting of 
lipid, apolipoprotein A1, and fluorescent marker. d, Transmission electron microscopy 
(TEM) image of the synthesized eHNP-A1 (scale bar=20 nm). e, Size distribution of the 
synthesized eHNP-A1. f, Composition of the eHNP-A1. 
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4.1). Such brain delivery efficiency is higher than that of other well-known NPs for 
brain targeting drug delivery,48 possibly due to the interaction with receptors on brain 
ECs. Confocal imaging analysis of the cryosectioned brain tissue confirmed that the 
systemically administered eHNP-A1s were localized around the cell nucleus (Figure 
4.2c). Further examination of the eHNP-A1 distribution in vascular and perivascular 
regions or in different cell types at the BBB can be done with the BBB chip.   
 
4.2.3 Nanoparticle transport analysis on chip 
  One challenge in CNS drug delivery research is to accurately quantify the 
transport of drug compounds into the brain at cellular and molecular levels. Our BBB 
chip allows for the monitoring of the interactions between cells and NPs but also 
enables us to quantify the distribution of NPs in vascular and perivascular spaces as 
well as in each cell type.  
  We quantified eHNP-A1 distributions in the vascular and perivascular spaces at 
the BBB and studied the transport mechanisms in a controlled manner. We 
hypothesized that when a NP solution is introduced into our BBB chip, NPs either 
Figure 4.2 Biodistribution of the eHNP-A1. a, Biodistribution of the eHNP-A1. b, 
Quantification of the relative fluorescence intensity in each organ (n=4 for each condition). 
c, eHNP-A1 accumulated in the mouse brain (scale bar=50 µm). 
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remain in the vascular channel, interact with HBMECs, or translocate into the 
perivascular channel in which NPs can interact with HBVPs or HAs (Figure 4.3a-c). 
With the results of eHNP-A1’s BBB penetration as shown in our animal study (Figure 
4.2), we used our BBB chip to investigate the mechanism by which eHNP-A1 can get 
into the brain. We tested the hypothesis that eHNP-A1 primarily leverages scavenger 
receptor class B type 1 (SR-B1) on brain endothelial cells to cross the BBB via 
transcytosis, one of the major transport mechanisms of natural HDL.93,94 After blocking 
SR-B1, the amount of eHNP-A1 remaining in the vascular channel significantly 
increased (Figure 4.3d), whereas the amount of eHNP-A1 translocated to the 
perivascular channel was not significantly changed (Figure 4.3e). This result indicates 
that blocking SR-B1 activity reduces eHNP-A1 uptake by HBMECs, whereas it may 
induce a compensatory upregulation of other receptors or determinants of endothelial 
transcytosis such as SNAREs.93,95 We then mapped the 3D distribution of eHNP-A1 in 
our BBB chip by compensating NP loss caused by the adsorption to the PDMS surface 
(Figure S 4.2). Our results revealed that block lipid transport-1 (BLT-1) treatment reduced 
the amount of eHNP-A1 that gets into the tissue (“EC uptake” and “perivascular 
channel”) by ~3 fold (Figure 4.3f,g). Cellular uptake of eHNP-A1 was further 
quantified using Fluorescence-activated cell sorting (FACS) analysis. The total portion 
of eHNP-A1 positive cells was decreased in the BLT-1 treated BBB models (Figure 
4.3h,i), indicating that SR-B1 mediates the cellular uptake of eHNP-A1 in our BBB chip 
as shown in previous study.93 In particular, the portion of perivascular cells (i.e. HBVPs 
and HAs) that have taken up eHNP-A1 was decreased by 38.5% and 53.8% respectively 
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with BLT-1 treatment, whereas the portion of HBMECs with eHNP-A1 was not changed 
(Figure 4.3j).  
 
Figure 4.3 Distribution of the eHNP-A1 in the BBB model. a, Schematic description of 
eHNP-A1 distribution in the BBB model showing (1) eHNP-A1 remaining in the vascular 
channel, (2) eHNP-A1 interact with endothelial cells (HBMECs), (3) eHNP-A1 
translocated to the perivascular channel, and (3-1) eHNP-A1 interact with astrocytes 
(HAs). b,c, Confocal images showing eHNP-A1s within the HBMEC monolayer (b) and 
HAs (c) in a BBB chip (scale basr=50 µm). d,e, Relative fluorescence intensity of sampled 
culture medium containing eHNP-A1 from the upper channel (d) and the lower channel 
(e) after 2 hours of eHNP-A1 incubation in the vascular channel (k: n=12; l: n=5, 
**p<0.01). f,g, Distribution of eHNP-A1 in control (f) and the BLT-1 treated 
microengineered BBB model (g). h,i, Representative Fluorescence-activated cell sorting 
(FACS) plot for the numbers of eHNP-A1 positive HBMECs and HAs in control (h) and 
BLT-1 treated BBB models (i). j, Cellular uptake of eHNP-A1 in the BBB chip quantified 
from FACS analysis (n=3). 
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 Conclusions 
  The brain-blood ratio of a drug concentration, a key parameter to estimate brain 
pharmacokinetics and brain-targeting efficiency, has been previously assessed using 
rodents by in situ brain perfusion, brain microdialysis, and neuropharmacokinetic 
study.96,97 Given the complexity of the techniques and species differences between 
humans and rodents, there is a critical need for new strategies that quickly and reliably 
measure how much drugs can penetrate to the brain parenchyma in a dose-dependent 
manner at multiple time points.98 Our BBB model integrated with precise time-lapse 
sampling and end-point FACS analysis allowed us to precisely quantify 3D 
nanoparticle distribution at the BBB. Compartmentalized structure of the BBB chip 
conferred the ability to measure the amount of molecules separately for each space, 
allowing for quantitative assessment of BBB penetrations. Quantitative analysis of 
cellular uptakes in the BBB chip enabled us to evaluate the targeting efficacy of 
nanoparticles at cellular levels. Moreover, our model provided an in depth mechanistic 
understanding of the interactions between the BBB and nanoparticles at cellular levels.  
  In summary, to assess NP transport across the BBB, we used a HDL-mimetic 
NP synthesized with our microfluidic technology, which we recently reported.99 Using 
our BBB chip, we demonstrated that eHNP-A1 is a potential CNS drug delivery system 
with their biomimetic ability to cross the BBB via SR-B1 mediated transcytosis. Our 
novel approach to 3D mapping of nanoparticle distributions in the vascular and 




 Materials and Methods 
Fabrication of the microfluidic device. The microfluidic device was fabricated with 
polydimethylsiloxane (PDMS; Sylgard 184; Dow Corning, Midland, MI, USA) using soft 
lithography.79 To create the PDMS slab for the upper layer, PDMS pre-polymer (10:1 
elastomer base to curing agent, wt/wt) was degassed and poured onto silicon wafers 
patterned with SU-8 (Microchem, Newton, MA, USA). The thin PDMS sheet for the lower 
layer of the device was created by spin coating an SU-8 patterned silicon wafer with a 
PDMS pre-polymer to a height of 250 µm. After curing the PDMS pre-polymer for 1 h at 
80˚C, inlets and outlets of the channels were formed with 1 mm diameter biopsy punch. A 
polycarbonate membrane (8 µm pore; Sterlitech Corp, Kent, WA, USA) treated with 5% 
3-aminopropyl-trienthoxysilane (APTES) solution (Sigma-Aldrich, St. Louis, MO, USA)80 
was sandwiched and bonded between the upper and lower PDMS layers using a plasma 
cleaner (Harrick Plasma, Ithaca, NY, USA). The fabricated device was then placed in a 
polystyrene box (Ted Pella Inc., Redding, CA, USA). The device and microchannels are 
sterilized with 70% ethanol and placed in a dry oven at 80˚C for 2.5 days to restore 
hydrophobicity of the PDMS surface. 
Cell culture. Immortalized human brain microvascular endothelial cells (HBMEC; 
Innoprot, Bizkaia, Spain) at passage 5-10 were maintained in endothelial cell medium 
(Sciencell, San Diego, CA, USA) on flasks coated with 50 μg/mL fibronectin (Sigma 
Aldrich). Human brain vascular pericytes (HBVP) and human astrocytes (HA) (Sciencell) 
were cultured on 1 mg/mL poly-l-lysine (PLL, Sigma Aldrich) coated flasks and 
maintained in astrocyte and pericyte medium, respectively (Sciencell). Both primary cells 
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between passages 3 and 5 were used for all experiments. Fibronectin and PLL coating 
procedures were achieved following the manufacturer’s instruction. 
Construction of the BBB chip system. Prior to seeding HBVPs into the center channel of 
the lower layer, the channel was coated with 50 µg/mL fibronectin (Sigma-Aldrich) for 1 
h at 37 ˚C while the device was placed upside down. Then HBVPs were seeded at 1 x 107 
cells/mL density into the center channel and incubate for 6 h to allow adhesion of cells 
onto the fibronectin-coated polycarbonate membrane. Then 1 x 107 HAs suspended in a 
100 μL of Matrigel solution (Growth factor-reduced; Corning, Corning, NY, USA) were 
seeded into the same channel that HBVPs are cultured. The final concentration of Matrigel 
was calculated to be 5 mg/mL. After gelation of Matrigel in the channel by incubating at 
37˚C for 30 min, cell culture medium was filled into the two side channels to avoid the gel 
drying out. The device was placed in the incubator at 37 ˚C for 6 h, and the upper luminal 
channel of the device was coated with 50 µg/mL fibronectin for 1 h at 37 ˚C. HBMECs 
were then seeded into the upper channel with the density of 7 x 107 cells/mL. The final cell 
number ratio between HBMECs and HBVPs in a device was 1.5:1, and the ratio between 
HBMECs and HAs was 2:1, which was optimized for HAs to cover ~99% of the 
perivascular surface of the endothelium. After 24 h of culture to stabilize cells in the 
microfluidic device, the upper channels were connected to PhD Ultra syringe pumps 
(Harvard Apparatus, Holliston, MA, USA) and exposed to the media flow with the flow 
rate of 16 µL/min to give cells the shear stress of 4 dyne/cm2, which corresponds to the 
shear stress levels in the brain.72 
Immunocytochemistry. To visualize cell-specific marker expression, 
immunocytochemistry was performed. Briefly, samples were fixed with 2% 
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paraformaldehyde (PFA; Santa Cruz Biotechnology, San Diego, CA, USA) for 15 min at 
RT. After permeabilizing in 0.1% Triton X (Sigma-Aldrich) in PBS for 15 min, the samples 
were blocked with 2% bovine serum albumin (BSA; Sigma-Aldrich) in PBS for 1 h at RT. 
Subsequently, the samples were incubated with primary antibodies at 4 ˚C overnight, 
washed three times with 1% BSA. Then samples were incubated with fluorescence-
conjugated secondary antibody for 6 h at 4 ̊ C to visualize targets. The following antibodies 
were used for immunocytochemistry: mouse anti-GFAP (1:200; Invitrogen, Carlsbad, CA, 
USA), chicken anti-mouse AlexaFluor 594) (1:200; Invitrogen) Nuclei were 
counterstained with 4,6-diamino-2-phenylindole (DAPI; Invitrogen) and stored in PBS 
before imaging. Fluorescently visualized samples were examined using a confocal 
microscope (LSM 700, Carl Zeiss, Oberkochen, Germany). 
Nanoparticle (NP) synthesis. The microvortex propagation mixer (µVPM) that we 
reported previously99 was used for the synthesis. Briefly, the µVPM was connected to 
syringe pumps (Harvard Apparatus) to introduce the solutions into the device. The 
precursor solutions including a lipid solution that was composed of 1,2-dimyristoyl-sn-
glycero-3-phosphocholine (DMPC; Avanti Polar Lipids, Alabaster, AL, USA) with a 
concentration of 2.75 mg/mL in ethanol, and a Apolipoprotein A1 from human plasma 
(Sigma-Aldrich) with a concentration of 0.2 mg/mL in PBS were added into the mixer. The 
flow ratio between the side streams and the center stream in the mixer was 5.5:1. The mixed 
solution was collected and then washed three times with PBS using a 10,000 M.W. 
centrifugal filter (EMD Millipore Corp., Darmstadt, Germany) at a speed of 3900 rpm for 
20 min. The size distribution of the final sample was measured with a Zetasizer Nano ZS 
(Malvern Instruments, Worcestershire, United Kingdom). Fluorescently labeled eHNPs 
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were synthesized with 1,1ʹ-Dioctadecyl-3,3,3ʹ,3ʹ-Tetramethylindotricarbocyanine Iodide 
(DiRʹ; Invitrogen) or a modified lipid precursor solution containing 15% (w/w) 1,2-
dimyristoyl-sn-glycero-3-phosphoethanolamine-N-(lissamine rhodamine B sulfonyl) 
(Rhodamine-DMPE; Sigma-Aldrich). The amount of protein of the final sample was 
quantified using the Micro BCA Protein Assay kit (Invitrogen). 
Biodistribution study. All animal experiments were reviewed and approved by the 
Georgia Tech’s Institutional Animal Care and Use Committee. 4-5 week-old male balb/c 
mice (Jackson Labs, city, state, USA) were given an irradiated dietary regiment until the 
mice were 21-22 weeks of age. For biodistribution study, 1 mg/kg of eHNP-A1 was 
systemically administered to the mouse via tail vein injection. Injection of 200 μL saline 
was served as control. 24 h after administration, mice were sacrificed and perfused with 
saline and 4% PFA for 15 min. Then organs (brain, heart, lung, liver, kidneys, and spleen) 
were harvested to visualize their DiR content using an in vivo imaging system (IVIS; 
Perkin Elmer, Waltham, MA, USA). To visualize the eHNP-A1 internalization inside the 
brain tissue, the harvested brain tissues were cryosectioned into 10 µm slices and stained 
with DAPI using the DAPI-containing antifade mounting medium (H-1200; Vector 
Laboratories, Burlingame, CA). The slides were then imaged under a confocal microscope 
(Zeiss LSM 780).  
Nanoparticle distribution study in a chip. Culture medium containing eHNP-A1 at a 
concentration of 10 µg/mL was introduced into the upper channel of the device. To block 
the NP transport via SR-B1, 200 µM of BLT-1 (Sigma Aldrich) was treated in the upper 
channel for 1 h prior to the NP incubation. Following 2 h of NP incubation with culture 
medium with or without BLT-1 (200 µM), 10 µL of culture medium was sampled from the 
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upper channel. The upper channel was washed with PBS and filled with Dispase (Corning) 
to digest Matrigel in the lower channel. After 30 min, 10 µL of the mixture of the culture 
medium and digested Matrigel from the lower channels were collected. To measure the 
concentrations of nanoparticles, fluorescence intensities of the culture medium injected 
into the upper channel, sampled from the upper channel (n=14 for control and n=13 for 
BLT-1), and the culture medium sampled from the lower channels (n=7 for control and 
n=5 for BLT-1) were measured using the Cytation 5 plate reader.  
Nanoparticle uptake study using flow cytometric analysis (FACS). Prior to seeding 
cells into the device, HBMECs and HAs were fluorescently labeled with CellTrackerTM 
(Deep Red and Green CMFDA, respectively; Invitrogen) as per manufacturer’s 
instructions. After 2 h of 10 µg/mL of NP incubation in the upper channel of the device, 
the devices were washed three times with PBS and 0.25% Trypsin-EDTA (Invitrogen) and 
Dispase (Corning) were injected into the upper channel and lower side channels, 
respectively. HBMECs and HAs were then collected in culture medium and spun down at 
1000 rpm for 5 min. Then cell mixture was fixed in 4% PFA (Santa Cruz Biotechnology) 
for 30 min and stored in ice-cold FACS buffer (PBS with 2% FBS (Invitrogen)) at 4 ˚C. 
The HBMEC and HA fractions in total sample (n=5 for control and n=6 for BLT-1) were 
obtained by BD FACSAria III Cell Sorter (BD Biosciences, San Jose, CA, USA) and 
quantitatively analyzed using FlowJo software (FlowJo LLC, Ashland, OR, USA). Debris 
and doublets were excluded using FSC-A/SSC-A, FSC-A/FSC-W, respectively. The cells 
were then gated for the appropriate markers for the cell type (Figure S 4.3). 
Calculation of nanoparticle distribution on a chip. Loss of the injected NPs in a device 
due to their non-specific adsorption to the PDMS surface was measured by sampling the 
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NP solution after 2 h of incubation in a device consisting of a single-layer of the vascular 
channel. The NP distribution in HBMECs was calculated as follows: 
(𝐻𝐵𝑀𝐸𝐶 𝑢𝑝𝑡𝑎𝑘𝑒𝑐𝑎𝑙𝑐𝑢𝑙𝑎𝑡𝑖𝑜𝑛)
=  (𝑇𝑜𝑡𝑎𝑙 𝑖𝑛𝑗𝑒𝑐𝑡𝑒𝑑 (100%)𝑆𝑎𝑚𝑝𝑙𝑖𝑛𝑔) −  (𝐿𝑜𝑠𝑠𝑠𝑎𝑚𝑝𝑙𝑖𝑛𝑔)                       
− (𝑉𝑎𝑠𝑐𝑢𝑙𝑎𝑟𝑆𝑎𝑚𝑝𝑙𝑖𝑛𝑔) −  (𝑃𝑒𝑟𝑖𝑣𝑎𝑠𝑐𝑢𝑙𝑎𝑟𝑆𝑎𝑚𝑝𝑙𝑖𝑛𝑔)  
Where (𝑉𝑎𝑠𝑐𝑢𝑙𝑎𝑟𝑆𝑎𝑚𝑝𝑙𝑖𝑛𝑔) , (𝑃𝑒𝑟𝑖𝑣𝑎𝑠𝑐𝑢𝑙𝑎𝑟𝑆𝑎𝑚𝑝𝑙𝑖𝑛𝑔) , and 
(𝑇𝑜𝑡𝑎𝑙 𝑖𝑛𝑗𝑒𝑐𝑡𝑒𝑑 (100%)𝑆𝑎𝑚𝑝𝑙𝑖𝑛𝑔) are fluorescence intensities of NP solutions sampled 
from the vascular channel, perivascular channel, and injected solution, (𝐿𝑜𝑠𝑠𝑠𝑎𝑚𝑝𝑙𝑖𝑛𝑔) is 
the loss of NPs in a device measured by sampling, and (𝐻𝐵𝑀𝐸𝐶 𝑢𝑝𝑡𝑎𝑘𝑒𝑐𝑎𝑙𝑐𝑢𝑙𝑎𝑡𝑖𝑜𝑛) is 
percentages calculated by the equation.  
 
 Supplementary Information 
  
 
Figure S 4.1 Ex-vivo biodistribution of eHNP-A1. Organ distribution of dye-loaded 
eHNP-A1 24 h after intravenous administration. Fluorescence signals of eHNP-A1 were 
detected in the brains as compared to the saline control. 
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Figure S 4.2 eHNP-A1 loss in a microfluidic channel due to the adsorption to the 
PDMS surface. a,b, Fluorescent images showing eHNP-A1 solution inside the vascular 
channel after 2 h of NP incubation before washing the channel (a) and after washing the 
channel with PBS (b). Single layer of the vascular channel without cells were used to 
measure the eHNP-A1 loss caused by adsorption to the PDMS. c, Fluorescence intensities 
in the vascular channel in images quantified using ImageJ, indicating the remaining NPs 
in the channel. The fluorescence intensities were normalized to that from the channel 
“before washing” (n=3 for each condition, **p<0.01). d, Fluorescence intensities of NP 
solutions before injecting into the microchannel (pre-incubation) and sampled from the 
microchannel after 2 h of incubation (post-incubation) measured with a plate reader, 
indicating working concentration of the NP solution (n=20 for pre-incubation and n=11 for 
post-incubation, ****p<0.001). The intensities were normalized to those of the pre-








Figure S 4.3 Example of gating strategy for flow cytometric analysis of eHNP-A1+ 
cells. a, Cell suspensions were hierarchically gated as follows: Cells were gated and debris 
were excluded using FSC-A/SSC-A. Single cells were selected using FSC-A/FSC-W gate. 
NP+ cells were distinguished with PE fluorescence. b, PE+/APC+ cells were considered as 
NP+ HBMECs. c, PE+/FITC+ cells were considered as NP+ HAs. 
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CHAPTER 5. CONCLUSIONS 
 Concluding Remarks 
In this thesis, I have presented a microengineered human BBB platform with 
physiologically relevant structure and function, offering its application in quantitative 
assessment of CNS drug delivery systems. The hybrid design of a microfluidic device 
combining two vertical layers with three parallel channels enabled reconstitution of the 
BBB structure by establishing a 2D intact brain endothelium and a 3D brain 
microenvironment with astrocytic network. The in vivo like physiology of astrocytes in 3D 
microenvironment as well as the characteristics of HBMECs with their BBB specific gene 
expressions in the BBB model were demonstrated. The three human BBB constituent cell 
types reconstituted the BBB-like structure in a device. Its function was validated with 
permeability and TEER measurements. Moreover, I for the first time quantified the 
polarized distribution of AQP4 in the BBB model, which has long been overlooked in 
existing in vitro BBB models. More importantly, the well-designed and validated BBB 
model precisely captured nanoparticle distributions in the vascular and perivascular regions 
of the BBB at cellular levels and demonstrated distinct cellular uptakes and BBB 
penetrations through receptor-mediated transcytosis of high-density lipoprotein-mimetic 
nanoparticles.  
Taken together, the present BBB model has great potential as a complementary in 
vitro model to existing in vivo models for predicting drug delivery across the BBB in a 
mechanistic manner for the treatment of CNS diseases. Thus, this human BBB model could 
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provide a widely useful tool for translational medicine research in particular for the 
modeling of neuroinflammation and reactive gliosis in neurological disorders. 
 
 Challenges and Future Work 
5.2.1 Cell sources 
Recent in vitro models have demonstrated the importance of cell source to mimic 
organ-specific function in vitro, as well as for human disease modeling.74,75 In particular, 
highly complex BBB organization requires brain-specific cells to be sourced appropriately 
for in vitro modeling, which secures the key characteristics including the tight barrier 
function and low permeability resulting from high expressions of BBB-specific 
proteins.5,9,69,70 Immortalized human brain cells are good candidates for standardized 
screenings due to their availability as well as indefinite proliferation while preserving their 
properties. Primary human brain cells display functional features that are more relevant to 
the cells in vivo, but their availability is limited with ethical issues and there is another 
issue with their batch-to-batch variability. Human induced pluripotent stem cells (iPSCs) 
differentiated into brain cells can provide a robust source that possess properties for human 
BBB models. Moreover, advances in the iPSC technology can be integrated into the BBB 




Among the commercially available hydrogels, Matrigel has the most similar 
components to the brain extracellular matrix, with laminin and collagen IV as major 
components. In the BBB model, to minimize the effects of Matrigel on astrocyte reactivity, 
I have cultured astrocytes in growth-factor reduced Matrigel. Although the cells grow well 
in Matrigel, there is one issue that can arise when maintaining the culture system for longer-
time. Due to its degradation over time, it is hard to maintain the 3D culture over 5 days, 
which restricts long-term drug screening or disease modelling. Moreover, there are other 
drawbacks such as Matrigel’s tumorigenic origin and batch-to-batch variation. Culturing 
astrocytes in well-characterized and tunable hydrogels may overcome the challenges in the 
current Matrigel-based model.   
 
5.2.3 Higher-throughput experimental setup 
The current BBB model allowed for multiple analyses including TEER 
measurement, nanoparticle sampling, and FACS analysis while the multiple devices were 
regulated by multi-syringe racks at the same time. Microfluidic parallelization technology 
that integrates multiple devices while preserving advantages of the microscale organ-on-a-
chip engineering will further provide higher throughput system.100 
 
5.2.4 Reduce the adsorption of molecules in a chip 
The present microfluidic device is made of PDMS, which has a critical 
disadvantage to perform high-precision sampling of biochemical molecules. It has been 
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reported that PDMS adsorbs many molecules due to its surface properties including 
porosity and hydrophobicity.101,102 To reduce the molecular adsorption to channel surface, 
the PDMS channel can be chemically modified using chemical vapor deposition or 
silanization.103 Moreover, a new microfluidic device made of other materials that have less 
adsorption of molecules, such as polystyrene may solve the molecular adsorption issue. 
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APPENDIX A. MICROFABRICATION OF THE HUMAN BLOOD-
BRAIN BARRIER CHIP 
A.1  Overview 
 This protocol includes the process for the fabrication and functional validation of 
the microengineered human blood-brain barrier (BBB) chip.  
The summary of this protocol is as follows: 
Development of the microengineered human BBB chip 
a. Fabrication of the chip 
b. Cell culture in the chip 
c. Flow initiation into a microfluidic channel 
Demonstration of the structure and function of the BBB chip 
a. Immunofluorescent staining 
b. Permeability assay 
c. TEER measurement 
  
Figure A 1 Fabrication-completed microengineered devices. 
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A.2  Development of the microengineered human BBB chip 
A.2.1 Chip fabrication 
Materials and equipment: 
✓ PDMS (Sylgard 184 Elastomer Kit) 
✓ Silicon wafer molds (Upper and Lower channel molds) 
✓ Polycarbonate membrane – 8 µm pore (Sterlitech PCTB8025100) 
✓ (3-Aminopropyl)triethoxysilane (APTES) (Sigma 440140) 5% solution in DI water 
✓ Diamond cutter 
✓ 1 mm biopsy punch  
✓ Clear plastic container (Ted Pella 139-75) 
✓ Kimwipes 
✓ 100 mm petri dish 
✓ Scissors 
✓ Precision knife 
✓ Tweezers 
✓ Benchtop microscope 
✓ Microscope glass slide  
✓ Scotch magic tape (3M 810) – for cleaning 
✓ Hot plate 
✓ Plasma cleaner 




1. Mix PDMS pre-polymer (33g for upper channel mold, and 11g for lower channel mold; 
10:1 elastomer base to curing agent, wt/wt), degas in vacuum chamber, and pour onto 
the SU-8 wafers patterned with microchannels. 
2. Cure PDMS on the upper channel mold in the 80 ˚C dry oven for 1 hour.  
3. Spin PDMS onto the lower channel mold using the following recipe: 
a) Step 1: 100rpm at 50rpm/s for 10 seconds 
b) Step 2: 250rpm at 50rpm/s for 93 seconds 
c) Cure at 100ºC for 5 minutes 
4. Cut out the upper PDMS slab and punch inlet/outlet holes using a 1mm biopsy punch 
(punch into the PDMS from the channel side). 
5. Cut out the lower PDMS layer and place lower channel onto a clean glass slide channel 
side up. 
6. Cut and treat polycarbonate membranes for bonding 
a) Heat APTES solution on the 80ºC hot plate for 20 min 
b) Plasma clean the both sides of the membrane for 1 min each 
c) Roughly cut out 3 mm x 10 mm sections of the polycarbonate membrane 
d) Soak the plasma cleaned membrane cutouts into the warmed APTES solution for 
20 minutes (While waiting for 20 min, do the steps 7 and 8) 
e) Dry the membrane cutouts on kimwipes  
7. Clean the channel side of the upper PDMS slab with tape 3 times. 
8. Clean the channel side of the lower PDMS layer with tape 3 times. 
9. Assemble PDMS components and membrane together. 
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a) Plasma clean the lower channel assembly and upper channel. 
b) Carefully apply a dried membrane cutout onto the lower channel, making sure to 
center and cover region where lower and upper channels overlap. 
c) Bring lower channel assembly and upper channel to the microscope and bond the 
two layers together. 
i. Find a cross (+) mark on the lower channel and clamp down the lower channel 
assembly with the microscope sample clips 
ii. Move the upper channel above the lower channel and focus the microscope 
lens so that both the upper and lower channels come into focus.  
iii. Carefully align the upper and lower channels so that the crosses in both upper 
and lower channels are aligned together. 
iv. Gently press the border of the membrane with tweezer. 
d) Place the chip in 100 mm petri dish and leave in the 80 °C dry oven for 30 minutes 
10. Cut the assembled chip half across the cross mark (The original chip contains two 
parallel BBB platform). 
11. Clean out a plastic box with N2 gas and place the assembled chip in a box to locate the 
outlet of the upper channel at the right side of the box and the inlets (branched) of the 
upper channel at the left side of the box. 
12. Pour 10 grams of PDMS around the chip to fix the chip in place. Bake in the 80 °C dry 
oven for 1 hour 
13. Mark the outlet on the lid of the box, remove the lid from the box and drill a hole into 
the lid using 7/64” bit. Reassemble the box with the lid. 
14. Sterilize the device with 70% Ethanol. 
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15. Leave the device in 80°C oven for > 2.5 days before cell culture to allow PDMS 
surfaces to recover hydrophobicity. 
 
 
A.2.2 Cell culture 
Materials and equipment: 
✓ Assembled device 
✓ 70% ethanol 
✓ PBS 1X 
✓ Fibronectin (50 µg/mL) (Sigma Aldrich F1141) 
✓ 1 confluent T75 flask of human brain vascular pericytes (HBVP) (passage 3-5) 
(Sciencell 1200) 
✓ 1 confluent T75 flask of human astrocytes (HA) (p3) (Sciencell 1800) 
✓ 1 confluent T75 flask of immortalized human brain microvascular endothelial cells 
(HBMEC) (p3-10) (Sciencell 1000) 
✓ Cell growth media (PM, AM, and ECM) (Sciencell 1201, 1801, 1001) 
✓ Mixed media for BBB culture (1:1:1 ECM, AM, and MM) 
✓ Growth factor reduced Matrigel (Corning 354230) – Check the endotoxin level of the 
lot before ordering 





1. Coat the lower side of the membrane with 50 μg/ml of fibronectin (in 1x PBS) for an 
hour at 37°C). 
2. Wash the channel twice with the culture media. 
3. Infuse 10 μl of HBVPs (1E7 cells/mL) into the lower channel and flip the whole chip 
upside down immediately after pinching the inlets and outlets of the lower channel. 
4. Add 500 μl of PBS in the plastic box to avoid media drying out. 
5. Refresh the cell culture media 1 hour after cell seeding. 
6. Culture HBVPs for 6 hours.  
7. Inject 10 μl of the astrocytes embedded hydrogel (in the case of Song Ih’s BBB, 5 
mg/mL of Matrigel) into the lower channel. (HA: 1E6 cells/mL) 
8. Flip the chip upside down. 
9. Let the hydrogel cure in the incubator (37°C) for 1 hour. 
10. Inject the cell culture media in the upper and side channels. 
11. Culture HAs for 6 hours. 
12. Coat the upper side of the membrane with 50 μg/ml of fibronectin for 1 hour. 
13. Wash the upper and side channels twice with the culture media. 
14. Infuse 15 μl of HBMECs (7E7 cells/mL) into the upper channel. 
15. Refresh the cell culture media in the upper channel 1 hour after cell seeding. 




A.2.2 Flow initiaion 
Materials and equipment: 
✓ PDMS 
✓ 1-10 µL tips 
✓ Syringe pump (Harvard apparatus PhD Ultra) 
✓ Tygon silicon tubing (Cole Parmer 95702-00) 
✓ PE60 tubing (BD Intramedic 427415) 
✓ 3mL syringes (BD 309657) 
✓ 30mL syringes (BD 302832) 
✓ 18G needles (BD 305180) 
✓ Clamps 
Procedure: 
1. Cut the 1-10 µL tips (Fig.1; half of the first line (1) and the first line (2) of the tip) and 
clog the fine tip with PDMS. Cure PDMS in the tips in 80 °C dry oven for 15 min. 
2. Autoclave the prepared plugs. 
3. Close the inlets/outlets of lower channels and branch of the upper channel as shown in 
Figure A 3. 
 








4. Prepare tubings (detailed description per 1 chip). 
a) 10 cm long tygon tubing 
b) ~50 cm long tygon tubings 
c) 3 mm long PE60 tubing adapters (x2)  
* DO NOT autoclave the PE60 tubing adapters. To sterilize, leave the tubing sets under 
UV overnight.  
5. Connect the PE60 tubing with the tygon tubings.  
6. Plug the culture medium filled tubing (10 cm long tubing, clamped) in the outlet of the 
upper channel (PE60 tubing into the outlet) and thread the tubing through the drilled 
hole in the lid of the plastic box. 
7. Add 30 mL of culture media in the plastic box. 
8. Place the device in a 37 °C incubator. 
9. Prepare a 30 mL syringe filled with 3 mL of culture medium and connect the syringe 
(18G needle) with a 50 cm long tubing. Fill the entire tubing by pushing the culture 
medium in the syringe.  
Figure A 3 Closure of the holes of the channels before applying flow into the upper 
channel. 
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10. Set up a syringe pump as described below: 
a) Step 1: (WITHDRAW) Ramp up flow rate from the minimum (0.08 µL for 30 mL 
syringes) to 16 µL/min for 1 hour 
b) Step 2: (WITHDRAW) Maintain 16 µL/min for 24 hours.  
11. Place the tubing connected syringe in a syringe pump and connect the tubings with the 
tubings connected to outlet of the device.  
12. Unclamp the tubes and start the pump run. 
 
A.3  Demonstration of structure and function of the BBB in a chip 
A.3.1 Immunofluorescent staining 
Materials and equipment: 
✓ BBB chip 
✓ Tweezer 
✓ PBS 1X 
✓ 2% Paraformaldehyde (PFA) 
✓ 0.1% Triton-X 
✓ 2% Bovine serum albumin (BSA) 
✓ 1% BSA 
✓ Primary antibodies 





1. After 24 hrs of flow application, clamp the tubing connected to the outlet of the upper 
channel and take the device out from the incubator. 
2. Remove the plugs and tubing from a chip gently using a tweezer. 
3. Wash the upper and side channels with pre-warmed PBS. 
• PBS and PFA are pre-warmed to avoid the endothelial cell shrinkage.  
4. Add pre-warmed 2% PFA into the upper and side channels and incubate at RT for 15 
min. 
5. Wash the upper and side channels with PBS for three times. 
6. Add 0.1% Triton-X into the upper and side channels and incubate for 15 min at RT. 
7. Wash the upper and side channels with PBS for three times. 
8. Add 2% BSA into the upper and side channels and incubate for 1 hour at RT. 
9. Wash the upper and side channels with PBS for three times. 
• After completing this step, the samples can be stored at 4˚C for later use.  
10. Add primary antibodies (diluted in 1% BSA to achieve a desired concentration – 3x 
higher concentration than the recommended concentration) into the upper and side 
channels and incubate at RT for 3 hours or overnight at 4˚C. 
11. Wash the upper and side channels with 1% BSA for five times. 
12. Add secondary antibodies (diluted in 1% BSA to achieve a desired concentration – 3x 
higher concentration than the recommended concentration) into the upper and side 
channels and incubate for 1 hour at RT or overnight at 4˚C. 
13. Wash the upper and side channels with 1% BSA for five times. 
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14. Add DAPI solution (1:200 in dH2O) into the upper and side channels and incubate for 
5 min at RT. 
• DAPI has poor solubility in PBS, but is soluble in water at 20 mg/mL 
15. Wash the upper and side channels with dH2O for three times. 
16. Wash the channels with PBS twice. 
 
A.3.2  Permeability assay 
Materials and equipment: 
✓ BBB chip  
✓ Culture medium (remain in a plastic box after applying flow can be used) 
✓ Tweezer 
✓ Clamps 
✓ Fluorescent probe (e.g. FITC-dextran) 
✓ Syringe pump (Harvard apparatus PhD Ultra) 
✓ Tygon silicon tubing (Cole Parmer 95702-00) 
✓ PE60 tubing (BD Intramedic 427415) 
✓ 1mL syringes (BD 309657) 
✓ 30mL syringes (BD 302832) 
✓ 18G needles (BD 305180) 
✓ 1.5 mL Eppendorf tube 
✓ Plate reader 
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Procedure: 
1. After 24 hrs of flow application, clamp the tubing connected to the outlet of the upper 
channel and take the device out from the incubator. 
2. Remove plugs from inlets/outlets of the left side channel and connect culture medium 
filled tubings (inlet: 10 cm long tubing, outlet: 5 cm long tubing) to inlets&outlets and 
leave the tubings clamped (Figure A 4). 
3. Collect the culture medium in a plastic container and add fluorescent probes in the 
culture medium to make a desired concetration (e.g. present study: 4 kDa and 40 kDa 
FITC-dextran -500 μg/mL in the cell medium). 
4. Add the fluorescent probe added culture medium into a plastic container. 
5. Place the device in the incubator, place the side channel outlet tube into a collection 
tube.  
6. Set up two syringe pumps as described below:  
a. Pump 1 (connected to the upper channel): (WITHDRAW) 16 µL/min for 1 hour 
b. Pump 2 (connected to the left side channel): (INFUSE) 4 µL/min for 1 hour.  
Figure A 4 Tubing and syringe pump setting for permeability assay. 
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• The flow rate in both upper and side channels are calculated to achieve 0 pressure 
differential, to see the diffusion-based permeability. 
7. Connect the upper outlet tubing to pump 1 and the side inlet tubing to pump 2. 
8. After 1 hour of experiment, read the fluorescence intensities of the collected medium 
using a plate reader. 
• Plain culture medium and fluorescent solutions with known concentrations (1x, 0.5x, 
0.25x …) should be measured together to obtain a standard calibration curve. 
 
A.3.3  TEER measurement 
Materials and equipment: 
✓ BBB chip  
✓ Culture medium (remain in a plastic box after applying flow can be used) 
✓ Tweezer 
✓ Sliver wire (A-M systems 783000) 
✓ Bleach  
✓ EVOM2 (Word Precision Instruments) 
Procedure: 
1. Cut the sliver wires with 3 cm length and soak two wires in bleach for 1 hour at RT. 
2. Wash the wires with PBS. 
3. After 24 hrs of flow application, clamp the tubing connected to the outlet of the upper 
channel and take the device out from the incubator. 
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4. Remove plugs from inlets/outlets of the right side channel and connect culture medium 
filled tubings (3cm long) to inlets&outlets. 
5. Connect culture medium filled tubing (3 cm) to inlet of the upper channel as well. 
6. Insert the two not bleached silver wires into the tubes connected to the upper channel 
and the two bleached silver wires into the tubes connected to the right side channel. 
7. Connect the other ends of the four tbes to a custom connector to fit EVOM2 
voltohmmeter for 4-point measurement. 













APPENDIX B. NANOPARTICLE DISTRIBUTION STUDY ON A 
BBB CHIP 
B.1  Overview 
This protocol describes the process for use of the microengineered human blood-brain 
barrier (BBB) chip for studying the nanoparticle distribution. 
B.2  Sampling and FACS sample preparation 
Materials and equipment: 
✓ Nanoparticle (NP) solution (fluorophore conjugated) 
✓ Appropriate fluorophore which is readable in a plate reader should be conjugated. 
✓ 2~3 fluorescent cell trackers with minimum overlaps of the ex/em wavelengths 
✓ Fluorophores should not be overlapped with that of NP. 
✓ Fluorophores should be able to be detected in FACS machine. 
✓ Dispase 100X 
✓ 0.25% Trypsin 
✓ PBS 1X 
✓ 4% PFA 
✓ 96-well plate 
✓ Cell culture media 
✓ FACS buffer 
✓ Plate reader 
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Procedure: 
1. Pre-treat cells with fluorescent cell trackers before seeding in a chip. 
2. Follow all the steps for cell seeding and flow application described above. 
3. Add 10 µL of NP solution (appropriate concentration for NP type (e.g. eHNP-A1: 100 
µg/mL) into the upper channel of the chip and incubate for appropriate time (e.g. 
eHNP-A1: 2 hours). 
4. Add a 10 µL drop of culture medium onto the inlet of the upper channel. 
5. Withdraw 10 µL of prewarmed PBS from the outlet of the upper channel using 1-20 
µL pipette and collect in a 0.6 mL tube. 
a. The collected media is used for measuring the amount of NP solution with a Plate 
reader. 
b. Add 5 µL of collected solution to 45 µL of culture medium (dilute the collected 
solution to 0.1x). 
c. Add 5 µL of original NP solution to 45 µL of culture medium. 
d. Place all prepared solutions and 50 µL of culture medium (blank; negative 
control) in a 96-well and measure the fluorescence intensity of the NPs with a 
plate reader. 
6. Wash the channels with prewarmed PBS once, and add dispase into the lower side 
channels and trypsin into the upper channel. 
7. Incubate the chips in 37 °C incubator for 10 min. 
8. Collect all the cells from the upper and lower channels to a 1.5 mL tube. 
9. Spin down the collected cells at 1200 rpm for 3 min. 
10. Aspirate supernatant and wash the cell pellet with PBS. 
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11. Spin down the sample at 1200 rpm for 3 min. 
12. Aspirate supernatant and add 200 µL of 4% PFA. Incubate for 3 min. 
13. Spin down the sample at 1200 rpm for 3 min. 
14. Aspirate supernatant, wash with 200 µL of PBS, and spin down. Repeat the step for 3 
times. 
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